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ACC  American College of Cardiology
Ad  Adenovirus
AHA  American Heart Association
CABG   coronary artery bypass grafting
CoDe  coincidence detection
DMEM	 	 Dulbecco’s	Modified	Eagle’s	Medium	
EDV  end-diastolic volume
ESV  end-systolic volume 
HFNEF  heart failure with normal ejection fraction
ICD	 	 intracardiac	defibrillator
IVUS  intravascular ultrasound
LacZ	 	 β-galactosidase
LCx	 	 Left	Circumflex	coronary	artery
LVAD  left ventricular assist device
LV   left ventricle 
LVEF  left ventricular ejection fraction
PCI  percutaneous coronary intervention
PET  positron emission tomography
RAA  Renin-angiotensin-aldosterone
SPECT  single photon emission computed tomography
VEGF  vascular endothelial growth factor
18-FDG	 	 18-flurodeoxyglucose
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81. Abstract 
Heart failure is a common and highly challenging medical disorder. The progressive increase 
of	elderly	population	is	expected	to	further	reflect	in	heart	failure	incidence.	Recent	progress	
in cell transplantation therapy has provided a conceptual alternative for treatment of heart 
failure. 
Despite improved medical treatment and operative possibilities, end-stage coronary artery 
disease present a great medical challenge. It has been estimated that therapeutic angiogenesis 
would be the next major advance in the treatment of ischaemic heart disease. Gene transfer to 
augment	neovascularization	could	be	beneficial	for	such	patients.	
We employed a porcine model to evaluate the angiogenic effect of vascular endothelial 
growth factor (VEGF)-C gene transfer. Ameroid-generated myocardial ischemia was produced 
and	adenovirus	encoding	(ad)VEGF-C	or	β-galactosidase	(LacZ)	gene	therapy	was	given	in-
tramyocardially during progressive coronary stenosis. Angiography, positron emission tomog-
raphy (PET), single photon emission computed tomography (SPECT) and histology evidenced 
beneficial	affects	of	the	adVEGF-C	gene	transfer	compared	to	adLacZ.	The	myocardial	dete-
rioration during progressive coronary stenosis seen in the control group was restrained in the 
treatment group. 
We observed an uneven occlusion rate of the coronary vessels with Ameroid constrictor. 
We developed a simple methodological improvement of Ameroid model by ligating of the Am-
eroid–stenosed coronary vessel. Improvement of the model was seen by a more reliable occlu-
sion rate of the vessel concerned and a formation of a rather constant myocardial infarction. We 
assessed the spontaneous healing of the left ventricle (LV) in this new model by SPECT, PET, 
MRI,	 and	 angiography.	 Significant	 spontaneous	 improvement	 of	 myocardial	 perfusion	 and	
function was seen as well as diminishment of scar volume. Histologically more microvessels 
were seen in the border area of the lesion. Double staining of the myocytes in mitosis indicated 
more cardiomyocyte regeneration at the remote area of the lesion. 
The potential of autologous myoblast transplantation after ischaemia and infarction of 
porcine heart was evaluated. After ligation of stenosed coronary artery, autologous myoblast 
transplantation or control medium was directly injected into the myocardium at the lesion area. 
Assessed by MRI, improvement of diastolic function was seen in the myoblast-transplanted 
animals, but not in the control animals. Systolic function remained unchanged in both groups. 
92. Introduction
End-stage	coronary	artery	disease	and	heart	failure	cause	significant	burden	to	western	society.	
Patients are disabled due to terrible chest pain or shortness of breath in minimal daily activities. 
When heart diseases are amongst the most common causes of death in western countries, these 
diseases present a state of ultimately weared out heart, with severe symptoms and a general lack 
of treatment choises.
End-stage	coronary	artery	disease	is	defined	as	persistence	of	angina	pectoris	symptoms	
CCS class III and IV despite maximally tolerated conventional medical treatments and in-
eligible coronary arteries to conventional revascularization procedure. Commonly, coronary 
disease is characterized by proximal stenoses of the main coronary vessels, rather easily dilated 
percutanously or bypassed surgically with modern techniques. However in end-stage coronary 
disease the coronary arteries are severely narrowed and diseased, and are beyond the most 
modern stenting procedures and surgical techniques. Many of these patients have already ex-
perienced multiple stentings and/or multiple coronary bypass procedures. These patients are 
systematically excluded from randomized trials of coronary bypass versus medical therapy and 
versus percutaneous techniques. Data on optimal management of this increasingly important 
and large patient subset are scarce (Schoebel and others 1997) .
Heart	failure	is	a	syndrome	caused	by	the	inefficiency	of	the	heart	to	provide	enough	blood	
to tissues. Most commonly this is due to LV malfunction (Mann and Bristow 2005). The basic 
modern treatment is based on optimal medication according to structural disease of the heart 
and symptoms. Patients with refractory symptoms despite maximal medication are offered 
extraordinary measures, such as chronic inotropes, mechanical assist devises or surgery. Any 
of these provide a stable long-term result.
While cardiac transplantation provides best results for end-stage coronary artery disease 
and heart failure, the patients are often old and thus beyond transplantation programs. Also, 
graft shortage is a worldwide dilemma. Thus, alternative means of treating these patient groups 
should be developed (Hunt and others 2005).  
One approach to cardiovascular ischemic diseases consists of augmenting neovasculariza-
tion with the aid of recombinant growth factors or gene therapy. It has been estimated that 
therapeutic angiogenesis would be the next major advance in the treatment of ischaemic heart 
disease. Furthermore, autologous transplantation of precursor or stem cells to replace dysfunc-
tional myocardium has emerged as a novel surgical alternative in the treatment of heart failure. 
In this study, our aim was to evaluate the duration of the biological effect of adenovirus medi-
ated	VEGF-C	in	ischemic	porcine	heart.	We	also	modified	the	ischemic	model	based	on	the	
Ameroid constrictor, to provide more consistent coronary artery occlusion. Finally, we aimed 
to test the effect of autologous intramyocardial myoblast transplantation in ischemic and inf-
arcted myocardium.
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3. Review of the literature
Heart failure
Heart failure is a syndrome in which the heart is unable to pump enough blood for body’s 
needs. Chronic low perfusion in tissues leads to neurohormonal changes, dyspnoea and fatigue 
- a state or syndrome called congestive heart failure. Heart failure is not an independent dis-
ease, but always a derivative of cardiac or extracardiac, congenital or acquired disease (Mann 
and Bristow 2005). In the 2001 report, the American College of Cardiology (ACC)/American 
Heart Association (AHA) introduced four stages in the development of heart failure (Table 1.). 
The	first	two	stages	recognize	patients	with	factors	that	predispose	them	to	the	developing	heart	
failure. Third stage includes patients with current or previous heart failure and a known heart 
disease. Fourth stage includes patients who have refractory heart failure despite optimal medi-
cal care and who may be suitable for focused treatments (Hunt and others 2001). New York 
Heart	Association	classification	categorizes	heart	failure	in	four	grades	(I-IV)	according	to	the	
degree of functional impairment conferred by the abnormality (Criteria Committee, New York 
Heart Association 1964). 
In a large European study, prevalence was higher in men and increased with age from 0.9% 
in subjects aged 55–64 to 17.4% in those aged 85 (Bleumink and others 2004). Heart failure 
contained	a	three-year	mortality	rate	41%	in	patients	<65	years	and	66%	for	patients	≥65	years	
(Cleland and others 1999). The heart failure is primarily caused by coronary artery disease and 
is the consequence of previous myocardial infarction. Other common causes of heart failure are 
hypertension and valve diseases. Together these three etiological factors explain a major deal of 
all heart failures (Sutton 1990). The less common causes of heart failure are eg. cardiomyopa-
thy,  pericardial diseases, congenital malformations, lung vessel and lung diseases excessively 
loading right ventricle, and tumours of the heart. 
The heart failure can be diastolic or systolic in nature (Aurigemma and Gaasch 2004). Ac-
cumulative evidence suggests that these phenomena cannot be entirely distinguished from each 
other, and the preferred term for diastolic dysfunction should be heart failure with normal ejec-
tion fraction (HFNEF). The proportion of patients with HFNEF in various studies ranges from 
13-74%, major of studies reporting a value of 40% (Vasan, Benjamin, Levy 1995). However, 
many	studies	are	compromised	by	variable	definitions	of	heart	failure	and	the	precise	threshold	
for what is considered to be a normal left ventricular ejection fraction (LVEF). Patients with 
primarily diastolic heart failure generally exhibit a concentric pattern of hyperthophic process 
and LV remodelling with a high ratio of wall thickness to chamber radius. On the other hand, 
systolic heart failure exhibits eccentric LV remodelling with increased chamber volume and 
slightly increased LV wall thickness (Devereux and others 2000). In systolic heart failure the 
ratio of mass to volume and LV wall thickness to chamber radius is decreased. 
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Stages of heart 
failure 
Stage Symptoms
A At risk for heart failure but without structural heart disease or symptoms
B Structural heart disease but without signs or symptoms of heart failure
C Structural heart disease with prior or current symptoms of heart failure
D Refractory heart failure requiring specialized interventions
Table 1. Classification of heart failure according to ACC/AHA statement.
Medical therapy for heart failure 
The current therapy for heart failure is mainly limited to the treatment of already established 
disease and is primarily pharmacological in nature. The introduction of angiotensin convertase 
enzyme inhibitors have changed dramatically the prognosis of heart failure. Renin-angiotensin-
aldosterone	system	attempts	to	retain	sufficient	blood	pressure	and	renal	glomerular	filtration	
in the low cardiac output state. Anyhow, the activation of this system has more deleterios effects 
than advantage on a long term. The inhibition of conversion of angiotensin I to angiotensin 
II restrains the pathophysiological effect of the latter. The same effect can be reached with 
angiotensin receptor I inhibitors. Also aldosterone inhibitors, such as spironolactone act to re-
vert renin-angiotensin-aldosterone system disorder. The use of angiotensin convertase enzyme 
inhibitors or angiotensin reseptor blockers are recommended in all the ACC/AHA stages of 
heart failure. Stage B patients are additionally recommended beta blockers in selected patients. 
On the Stage C patients diuretics, digitalis, aldosterone inhibitors and hydralazine or nitrates 
are recommended. On the patients with a refractory heart failure despite optimal medical care 
staged as D, extraordinary measures such as chronic inotropes, mechanical support, heart 
transplantation or surgical treatment can be offered (Hunt and others 2005). 
Surgical treatment for heart failure 
When assessing the surgery as an option for heart failure, there are no guidelines or clear 
algorithms as to which operation would suit an individual patient the best. Coronary surgery 
may improve the contractility of stunned or hibernating myocardium in 60% to 70% of cas-
es (Elefteriades and others 1993; Langenburg and others 1995). A critical mass of reversible 
ischemic myocardium must be present to attain a recovery in the left ventricular function. 
As	heart	 failure	progresses,	changes	 in	 the	 left	ventricular	configuration	cause	the	papillary	
muscles to stretch out of shape. Mitral valve regurgitation repair in the case of inappropriate 
approximation improves prognosis in heart failure patient population, but the long-term results 
are unsatisfactory (Ngaage and others 2008). Valve replacement surgery might improve exer-
cise tolerance and quality of life in patients with heart failure with a concomitant other valve 
disorder. A number of studies have shown that heart failure symptoms can be improved with a 
biventricular pacing or cardiac resynchronization therapy (Bristow and others 2004; Cleland 
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and others 2005). Left ventricular surgical restoration by excluding the noncontractile portion 
of the anterolateral left venricle with or without revascularization or mitral valve correction, 
improves left ventricular function and decelerates the remodelation process, when applied to 
appropriate patients (Athanasuleas and others 2004). Prosthetic devices for ventricular remod-
elling surgery in which the heart is wrapped in a mesh-like devise, have been introduced with 
to some extent positive results (Acker 2004). Implantation of left ventricular assist devises has 
been	shown	 to	be	expensive	with	poor	 long-term	results	and	significant	complications.	Two	
years after implantation of such devise, there are almost no survivals, although the patient 
population receiving the pumps enjoy improved quality of life compared to the control patients 
(Rose and others 2001). Batista procedure was introduced during the mid-1990s for patients 
with	heart	failure	and	dilated	LV.	This	operation	consists	of	removing	a	flap	of	heart	muscle	
from the LV to shrink the size of the ventricle and improve its geometry, thus improving the 
efficiency	of	cardiac	function.of	patients	with	severe	heart	failure.	In	a	series	of	59	patients	with	
severe heart failure and left ventricular dilation. 25% improved, 33% of the patients rapidly 
deteriorated, and the remainder had only transient improvement in cardiac function after the 
surgery, after which deterioration again set in.   After these results, general interest in this op-
eration rapidly diminished (Starling and others 2000).  Dynamic cardiomyoplasty is a method 
in which autologous latissimus dorsi muscle is wrapped around the heart as a pedicle graft. 
Stimulation of the graft can be synchronized with cardiac systole. Mortality in this operation 
has been descibed less than 10% and 80-85% or the survivals show improvement in NYHA 
class (Salmons 2008). For patients with end-stage heart failure the only relevant surgical option 
would be heart transplantation (Hunt 2006). Anyhow, transplantation is restricted by organ 
shortage and immunosupression. Also the contraindications of heart transplantation rule out a 
major part of the end stage heart failure patients. Thus, although heart transplantation is of ma-
jor importance for an individual recipient, its overall impact is limited. The use of xenografts 
is an alternative option which would resolve many problems concerning heart transplantation, 
but it is still beyond a clinical option at present (McGregor and others 2005).
Experimental models of heart failure
Pressure overload of the heart can be used to study the myocardial response to increased work. 
In the creation of right ventricle overload, the technique of pulmonary trunk banding is similar 
to in the Blalock-Hanlon operation in transposition of great arteries in infants. This maneuver 
produces hypertrophy of the right ventricle and failure takes place only after severe degrees 
of constriction. Similar models with supravalvar aortic constriction produces pressure loading 
of LV (Henderson and others 2007). LV pressure loading can also be produced pharmacologi-
cally by administration of corticosteroids. Occlusion of renal artery or unilateral nephrectomy 
and contralateral renal artery clipping leads also to hypertension and eventually left ventricular 
hypertrophy. 
Volume	overload	 can	be	performed	at	 simplest	by	 intravenous	 infusion	of	 excess	fluids.	
This kind of model can be used to study pulmonary congestion. Surgical instrumentation of 
aortocaval	fistula	leads	to	right	side	volume	load	and	this	kind	of	model	has	been	produced	in	
rat and dog. Similarly a chronic right side volume overload can be created by causing an atrial 
septal defect. LV volume overload can be produced by creation of aortic valve incompetence. 
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These situations provide a model of heart dysfunction clinically relevant to surgical conditions 
(Ryan and others 2007). 
Myocardial infarction is the most employed model of heart failure. This kind of model 
resembles clinical situation, but the amount of the infarction appears to be a challenge. Lesser 
infarction leads to compensatory changes, and excessive myocardial loss causes cardiogenic 
shock and death. Coronary occlusion can be extravascular or intravascular in nature (Schmitto 
and others 2008). 
Cardiomyopathy occurs spontaneously in Syrian hamsters and turkeys, so that heart failure 
can	be	produced	congenitally	by	specific	breeding	programs.	Primary	myocardial	disease	can	
also be produced by a variety of compounds toxic to myocardium. Furazolin, adriamycin (Lu 
and others 2008) and barbiturates have been used successfully to produce heart failure. Several 
other compounds such as catecholamines and alcohol have been used for cardiac depression. 
Also chronic hypoxia and sustained rapid atrial pacing lead to myocardial dysfunction (Moe 
and Armstrong 1999; Smith and Nuttall 1985).
Concept of heart regeneration 
Zebrafish	has	been	demonstrated	to	response	to	apical	heart	amputation	by	regeneration	of	LV	
with only a small deposits of collagen. After a removal of 20% of the myocardium a new ven-
tricular wall of compact myocardium was created by cardiomyocyte proliferation. It appeared, 
that these proliferating cells migrated from the adjacent healthy epicardium (Poss, Wilson, 
Keating 2002). Anyhow, no such regenerative healing has proven to exist in mammalian heart, 
in which myocardial infarct heals by means of extensive scarring (Robey and Murry 2008). 
Human heart is a post mitotic organ responding mainly by myocyte hypertrophy, cellular 
reorganisation	and	fibrosis	 to	excessive	 load	and	hypoxic	 trauma.	According	 to	 this	dogma,	
human hearts do not regenerate. Anyhow, evidence of myocyte proliferation has been observed 
in histological studies of hearts of end stage failure, where 140 mitosis per 1 million cells was 
observed (Kajstura and others 1998). Control hearts showed one tenth the amount of mitosis. In 
another study, myocardial samples were collected of 13 patients, who had died in myocardial 
infarction 4 to 12 days previously. In these samples, mitotic myocyte nuclei was found in 4 per-
cent of adjacent to the infarction and 1 percent in the remote areas (Beltrami and others 2001). 
Mitosis is a process of one hour duration and the authors propose, that the rather high mitotic 
index	is	evidence	of	the	clinically	significant	cellular	hyperplasia.	
Calculations of the rate of apoptosis added to the new information of proliferation raised 
suspicion of the slow regeneration and cell renewal in the human heart. It has been proposed 
that part of this phenomenon can be explained by artifacts (Schaper, Elsasser, Kostin 1999). 
More profound analysis of the replicating myocytes has shown, that the size of the myocytes in 
mitosis	is	significantly	smaller	than	the	size	of	an	average	cardiomyocyte	and	the	origin	of	the	
new cell might be extracardiac. Y-chomosome positive cardiomyocytes in male heart transplant 
recipients, who had female donors, lead to high suspicion of external source of these new car-
diac cells (Quaini and others 2002; Bayes-Genis and others 2002). The possibility of migration 
of the cells from the allograft remnants has been challenged by groups, who have transplanted 
extracardially different types of marked cells and reported the engraftment of these cells to 
damaged heart. Only a small fraction of these cells differentiate into cardiac myocytes (Jackson 
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and others 2001). They mainly demostrate blood cells, predominantly granulocytes, but of the 
part of the cells differentiating into cardiac cells have resembled endothelial cells in many stud-
ies (Balsam and others 2004; Nygren and others 2004). The results of the studies in this area of 
research are complex and yet unresolved. 
Cell therapy for heart failure
Cell-based cardiac repair offers the promise of alleviating heart injury by reconstituting or 
maintaining	cardiac	specific	tissue	(Orlic	and	others	2001).	The	preliminary	studies	were	con-
ducted with dedicated cells such as myoblasts (Chiu, Zibaitis, Kao 1995), but soon after the 
field	expanded	to	an	array	of	cell	types	including	bone	marrow	cells	(Bittner	and	others	1999),	
endothelial progenitors (Asahara and others 1997), mesenchymal stem cells (Pittenger and oth-
ers 1999), resident cardiac stem cells (Beltrami and others 2003), and embryonic stem cells 
(Westfall and others 1997). There has been numerous preclinical studies showing improvement 
in animal cardiac failure models, yet the mechanism of the improvement has remained obscure. 
Anyhow, the hypothesis of cardiac failure reversal or prevention has gained widespread atten-
tion and early-stage clinical trials have been launched (Assmus and others 2007; Chen and 
others 2004; Janssens and others 2006; Lunde and others 2006; Schachinger and others 2006; 
Wollert and others 2004). 
Routes for cell delivery
Transvascular route is suitable for patients undergoing percutaneous coronary interventions 
(PCI).	The	bone-marrow	derived	cells	can	be	infused	during	the	balloon	inflation,	when	coro-
nary	blood	flow	and	thus	the	cell	washout	is	minimal.	Such	intracoronary	infusion	would	also	
permit to deliver the cells to a certain area. In the setting of myocardial infarction, the activa-
tion of adhesion molecules and chemokines enhance the engraftment of the transplanted stem 
cells (Strauer and others 2002). Thus, the cell transplantation at the time of myocardial infarc-
tion and reperfusion seem a reasonable option. Intravenous stem cell transplantation is an ad-
ditional option in the case of acute myocardial infarction, but the amount of the cells homing 
to the heart is low (Kocher and others 2001a). Since skeletal myoblasts do not extravasate and 
may cause microembolization after coronary infusion, the intravascular route in not a possible 
option. The transplantation of myoblast cells in to the heart requires direct cell injection to the 
myocardium or other method of topical application.
Direct injection of the cells into the left ventricular wall can be performed via transepicar-
dial or intravascular route. Intravascular direct myocardial injections can be performed endo-
cardial or  transcoronary vein injections (Siminiak and others 2006). Catheter based transen-
docardial injection is performed using a needle catheter directed perpendicular to the inner 
surface of the target area an electromechanical mapping of the endocardial surface (Rutanen 
and others 2004c). The delivery of the cells by direct intraventricular injections has been prov-
en	to	be	feasible,	but	the	method	has	certain	difficulties.	The	LV	as	a	moving	target,	especially	
post-infarction	thin	wall	areas,	might	appear	technically	demanding.	Also	the	back-flush	of	the	
cells from the puncture holes is probable.  Catheter based cell delivery through coronary veins 
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consists of a catheter based endovascular system incorporating an intravascular ultrasound 
(IVUS) source and an extendable needle. After placing the catheter system into the target 
coronary vein, the IVUS is used to orient the direction of the needle according to pericardium, 
ventricular myocardium and the corresponding artery as landmarks. The pre-shaped Nitinol 
needle is oriented parallel to the ventricular wall (Sherman and others 2006). 
Myoblast cells
Skeletal	muscle	is	composed	of	multinucleated	cells	(muscle	fibers),	which	may	be	10-100μm	
thick and up to 15 cm long. These cells consist of transverse striations due to periodic alterna-
tion of isotropic and anisotropic bands. The nuclei of these cells lie immediately beneath of the 
cell	surface	and	are	scattered	in	the	direction	of	the	long	axis	of	the	muscle	fibers.	Skeletal	mus-
cle nuclei have lost the ability to divide and can be considered simply as transcriptional units. 
Already at 1961 Mauro et al reported seeing under electronic microscopic view, mononucleated 
cells	under	the	basement	membrane	of	the	muscle	fiber	but	not	fused	with	the	main	muscle	fiber	
(Mauro 1961). Mauro suggested these cells to be dormant myoblasts that failed to fuse with 
other myoblasts and are ready to activate, when the main multinucleate cell is damaged. They 
named the cells as satellite cells. This highly speculative suggestion turned out to be right. The 
potential role of satellite cells in repair has been under investigation in several morphological 
and	functional	studies.	The	simplified	description	of	satellite	cell	has	been	challenged	recently,	
indicating that under this name is a heterogeneous hierarchical population of cells. This popu-
lation is composed of a small number of satellite stem cells and a larger number of committed 
myogenic progenitors (Kuang and others 2007). There is also evidence, that rare subpopula-
tions of bone marrow cells  (Ferrari and others 1998; Gussoni and others 1999), a minority of 
circulating cells (Torrente and others 2003), or cells emanating from blood vessels (Sampaolesi 
and others 2003) can also adopt myogenic fate under certain circumstances. The descendants 
of activated satellite cells are called myogenic precursor cells or skeletal myoblasts.  These cells 
are able to undergo multiple rounds of division prior to terminal differentiation and fusion to 
form	multinucleated	myofibers	(Le	Grand	and	Rudnicki	2007).
Myoblast transplantation therapy
The	finding	of	myoblast	and	satellite	cells	aroused	a	high	hope	for	possible	clinical	applica-
tions. The myoblast cells have several advantages. Satellite cells are able to differentiate and 
fuse	to	augment	existing	muscle	fibres	and	to	form	new	fibres.	These	cells	are	involved	in	the	
normal growth of muscle, as well as regeneration following injury or disease. In undamaged 
muscle, the majority of satellite cells are quiescent; they neither differentiate nor undergo cell 
division. In response to mechanical strain, satellite cells become activated. Activated satellite 
cells initially proliferate as skeletal myoblasts before undergoing myogenic differentiation. The 
main advantages of the myoblasts include autologous origin, which overcomes the problems as-
sociated	with	immunosuppression.	The	cells	are	easily	harvested,	they	are	rather	easily	purified	
and	they	show	substantial	proliferative	potential	allowing	significant	increase	in	cell	number.	
Myoblasts are resistant to ischemia, which theoretically enhance the engraftment at a trans-
plantation site of less vascularized tissue (Menasche 2008). Although rhabdomyosarcoma has 
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been proposed to be origin of satellite cells, the advanced state of differentiation in myoblast or 
myogenic	cells	eliminate	the	possibility	of	tumorigenity	(Tiffin	and	others	2003).	
Studies in mdx mouse, a mouse strain lacking muscular dystrophin as in Duchenne muscu-
lar dystrophy, showed strong potential of myoblast transplantation (Partridge and others 1989). 
However, despite the promising results in mouse model, clinical trials conducted in humans 
showed very limited success (Huard and others 1992). The disappointing shift from rodent 
model to man, raised questions of the drawbacks of the myoblast transplantation. Indeed, many 
adverse events have been described following myoblast injection to muscle. Beauchamp et al 
showed, that massive cell death ensue the myoblast transplantation to mouse mucles, the sur-
vival being less than 1% after four days (Beauchamp and others 1999). In this study, Radioac-
tively labelled male myoblast cells were injected to female mouse. Despite the radiolabels and 
Y-chromosomes diminished initially linearly and substantially during time, at the day four the 
ratio of the radiolabels and Y-chromosomes showed, that the surviving population of the trans-
planted	cells	were	dividing.	The	investigators	were	able	to	find	within	the	transplanted	cells,	a	
population of in vitro slowly dividing cells, which survive and undergo rapid proliferation in 
vivo	after	transplantation.	This	finding	was	later	supported	by	Montarras	et	al,	who	were	able	
to	isolate	by	flow	cytometric	means	satellite	cells	(nongranular,	Pax7+,	CD34+,	CD45–,	Sca1–	)	
from	Pax3GFP/+	mouse	diaphragm.	The	ability	of	these	cells	to	contribute	to	tissue	reconstitu-
tion	in	mdx	mouse	was	not	increased	by	in	vitro	proliferation.	Conversely,	the	amplification	of	
cell number seemed not change the tissue reconstitution rate of a cell population. 
The culture of muscle progenitor cells before grafting markedly reduced their regenerative 
efficiency	in	a	way,	that	the	culture	expansion	yielded	the	same	amount	of	muscle	as	the	number	
of cells from which the culture was (Montarras and others 2005). Limited proliferative capacity 
of somatic cells explained by telomerase shortening includes satellite cells (Decary and others 
1997). Telomere shorten at each cell division and once the telomere becomes too short, a DNA 
damage signal is generated triggering the p53 expression and proliferative senescence. The 
poor dispersion of the injected cells might also be part of the undesirable regenerative effect of 
the myoblasts (Skuk and Tremblay 2003). 
Myoblast cell therapy for heart failure
The mechanisms of cell transplantation to improve the function of damaged myocardium has 
several explanations. The electromechanical coupling with the recipient heart and the trans-
planted cells participating in a functional syncytium with the host myocardium is most obvi-
ous, but improbable explanation. The engrafted myoblasts form large myotubes, which pos-
sibly contract according to the host myocardial cells due to the mechanical stress. The lack of 
connexin-43 expression of the myoblasts prevent the cells to be electrophysically connected 
to surrounding cardiomyocytes (Reinecke and others 2000), but the myoblasts retain their ex-
citability	and	can	generate	action	potentials	in	the	presence	of	field	stimulation	(Leobon	and	
others 2003). Anyhow, the detected improvement of systolic function may be mediated by 
paracrine factors secreted by the engrafted cells (Kinnaird and others 2004). Enhanced forma-
tion of blood vessels has been detected after cellular transplantation and increased expression 
of variety of growth factors observed. In a hibernating or stunned myocardium it has been 
noted, that improved perfusion promotes the recovery of systolic function. The myoblasts may 
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fuse with cardiomyocytes forming cardiac-skeletal hybrid cells,  as a rare event (Reinecke and 
others 2004). In vitro these fused cells resembled morphologically skeletal myotubes, while in 
vivo they were similar to cardiomyocytes. 
Another explanation would be the limitation of postinfarction LV remodellation. Such a 
mechanism is dependant on the timing of the cell transplantation, because notable reversal of 
severely remodellated LV is not likely, whereas early postinfarction cell grafting would inhibit 
the post-infarction expansion (Formigli and others 2007). Skeletal myoblast transplantation has 
also	been	associated	with	a	significant	attenuation	of	matrix	metalloproteinase-2	and	-9	up-reg-
ulation	in	a	mouse	model	thus	affecting	to	the	degree	of	fibrosis	(Murtuza	and	others	2004).	
 
Human studies of myoblast therapy for heart
Skeletal	myoblasts	were	the	first	form	of	myocardial	cell	replacement	therapy	to	enter	the	clini-
cal arena in 2000 (Menasche and others 2001). Menasche et al reported a case of autologous 
myoblast transplantation in a patient undergoing coronary artery bypass grafting (CABG) sur-
gery. The patient suffered severe heart failure with LVEF 21% and cardiac output 1 L/min. 
They injected 800 million cells at the free inferior wall at the area of infarction. Five months 
after	the	surgery,	the	symptoms	had	relieved	significantly	and	echocardiography	showed	im-
proved systolic thickening at the site of transplanted cells. Positron emission tomography 
showed	improved	tracer	uptake	at	the	inferior	wall.	LVEF	was	measured	30%	at	five	months	
after the surgery. The patient died 17,5 months after the operation due to stroke caused by acute 
proximal subclavian artery occlusion. At autopsy, histological analysis showed presence of 
multinucleated	myotubes	embedded	within	the	fibrosis	measuring	up	to	4mm	in	length	without	
any	inflammation	or	fibrosis	or	neovascularization.	These	cells	were	aligned	to	the	same	direc-
tion as the adjacent cardiomocytes (Hagege and others 2003). 
Several feasibility and safety pilot studies followed. In Paris, ten patients received myoblast 
transplantations during CABG surgery. All the patients had severe left ventricular dysfunction 
with LVEF less than 30% and a non-viable post-infarction scar area detected by dobutamine 
echocardiography,	18-fluorodeoxyglucose	(FDG)	PET.	These	patients	received	an	average	of	
871 x 106 autologous myoblasts at the area of infarction. One patient died unrelated to the cell 
transplantation. All the other patients had uneventful recovery. Four patients out of ten suffered 
sustained			ventricular	tachycardia	and	were	implanted	with	an	internal	defibrillator.	Because	
of the nature of the heart disease itself, the etiology of the arrhythmias remained obscure. 
Echocardiographic analysis showed that 63% of the cell-implanted scar segments (14 out of 22) 
demonstrated improved systolic function (Menasche and others 2003). 
Herreros et al treated twelve patients with simultaneous myoblast transplantation and 
CABG. The cells were implanted at akinetic or dyskinetic areas of LV via direct transepicardial 
injections. Echocardiography revealed a marked improvement in regional contractility in those 
cardiac	segments	treated	with	skeletal	myoblast	and	8F-FDG	PET	studies	showed	a	significant	
increased in cardiac viability in the infarct area 3 months after surgery. The mean improvement 
in the LVEF was 18% (Herreros and others 2003). 
In a multicenter study conducted by Dib et al., 24 patients received myoblasts in a direct 
transepicardial injections at a simultaneous CABG operation (Dib and others 2005). Additional 
6 patients, who received left ventricular assist device (LVAD) as a bridge to transplantation had 
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myoblast injections. The amount of the myoblasts in the CABG group was 10-300 X 106 in a 
dose	escalating	manner	and	the	dose	in	the	LVAD	group	was	a	fixed	300	X	106.	The	main	end	
point in the study was the appearance of adverse effects. In the LVAD group also the engaftment 
of the myoblasts were assessed in histological studies. For both the CABG and LVAD groups, 
the transplantation procedure was clinically well tolerated, and the myoblasts were delivered 
successfully. No deaths or arrhythmias occurred during surgery or injection of the cells. Mini-
mal bleeding from the injection sites was seen on occasion. Four deaths occurred during the 
four year follow-up period: 3 in the LVAD group and 1 in the CABG group. None of them were 
deemed related to the myoblasts or cell transplantation procedure. There was improvement in 
viability detected by MRI and PET in the area of the myoblast transplantation in the CABG 
group. But none of the hearts receiving less than 300 x 106 cells showed improved viability. 
The mean baseline LVEF, measured by echocardiography, for the CABG patients was 28% at 
baseline and 36% at 24 months’ follow up. The average end-diastolic volumes decreased from 
an average baseline 187 mL to 144 mL at 24 months. Because this procedure was combined 
with bypass surgery in the absence of a control arm, the improvement in LVEF, LV dimensions, 
and LV volumes, as related to cell transplantation, are unknown. In the hearts in the LVAD 
group	areas	of	surviving	myoblasts	were	seen	in	trichrome-stained	sections	and	confirmed	by	
use	of	the	skeletal	muscle-specific	myosin	heavy	chain	antibody,	MY-32.	No	data	of	the	number	
of the myoblasts surviving transplantion was obtained (Pagani and others 2003). 
Smits et al. used endoventricular NOGA mapping and injection system to percutaneously 
transplant autologous myoblasts into an area of postinfarction injury (Smits and others 2003). 
Only	five	patients	were	enrolled	in	the	study	and	the	small	sample	size	and	the	lack	of	control	
group	restrains	making	further	conclusions	of	the	efficacy	of	the	procedure.	Anyhow,	this	study	
shows feasibility of the approach and the safety from a procedural point of view. An increase in 
the LVEF was observed in the LV-cinegraphy, but not in SPECT or magnetic resonance imag-
ing	(MRI).	A	subanalysis	of	this	study,	where	additional	five	patients	were	enrolled	(total	n=10),	
consisted of regional and global LV function assessment by two-dimensional echocardiography 
with dobutamine infusion and tissue Doppler imaging. These studies showed an improvement 
in the systolic velocity at the myoblast transplanted LV wall and improved global LV function 
during low-dose dobutamin infusion, indicating an improvement of contractile reserve (Biagini 
and others 2006). 
In another study performed by the same group, a sole procedure of transendomyocardial in-
jections of autologous myoblasts were performed. At six months follow-up, an increased LVEF 
and cardiac output, a reduction of systolic LV volume and a trend towards improved stroke 
work	were	 observed.	 These	 hemodynamic	 improvements	were	 confirmed	 at	 one	 year	 after	
the	myoblast	transplantation	by	pressure-volume	loops	analysis,	where	significant	increase	in	
stroke volume, contractility and of diastolic stiffness was seen (Steendijk and others 2006).  
In	the	first	multicentre	study	of	myoblast	transplantation,	the	safety	and	efficacy	of	percu-
taneous transendocardial skeletal myoblast injection as a sole procedure in congestive heart 
failure patients was assessed. 15 patients were enrolled in the study. The mean LVEF was 
34.4±10.3 and a mean 6±4 years had passed after myocardial infarction .The patients received 
216±119	x	106	cells	via	 transendocardial	 route	with	NOGA	or	fluoroscopy	guided	 injection	
catheter.	After	treating	the	first	6	patients,	the	protocol	was	amended	because	of	a	sudden	death	
due	to	arrhythmia.	The	additional	patients	were	required	to	receive	an	intracardiac	defibrillator	
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(ICD) prior to the procedure. After 1 year follow-up 13 patients were alive. Stress echocardi-
ography showed improvement at rest and under low dose dobutamine stress, but there was no 
change in the LVEF (Smiths and others).
POZNAN-trial was similarly a catheter-based study, but the injection route was via car-
diac veins (Siminiak and others 2005). Dobutamine stress echocardiography was performed 
to screen patients of a non-viable transmyocardial scar. Ten patients were enrolled in the study. 
Nine out of 10 patients received the myoblast transplantation according to the study plan. The 
patients received up to 100 x 106 cells within 2-4 injections. In one patient, technical issues 
concerning a valve at the bifurcation of the great cardiac vein prevented the treatment injec-
tions. After 6 months the NYHA class improved in all nine patients and all subjects were in 
class I during follow-up. Ejection fraction evaluated independently by two blinded experienced 
investigators increased 3–8% in six out of nine cases, and no change in the LVEF, despite im-
provement in the NYHA class, in the remaining three patients was observed.
All these aforementioned studies are not randomized and they lack a decent control group. 
The	first	phase	II	trial,	Myoblast	Autologous	Grafting	in	Ischemic	Cardiomyopathy	trial	evalu-
ated the effect of autologous skeletal muscle myoblasts in patients with chronic heart failure 
who are undergoing coronary bypass. Inclusion criteria consisted of a history of myocardial 
infarction LVEF 15-35% and planned for CABG operation. The primary endpoint of the trial 
was improvement in LVEF observed in echocardiography and the secondary endpoint was 
15% difference in 1-year major adverse cardiac events. The primary bioactivity endpoint was 
recovery of the wall motion in the areas of infarction and the myoblast replacement therapy. 
Secondary bioactivity endpoints were global LV function and volumes, Doppler tissue imag-
ing sub-study, PET sub-study (Menasche and others 2008a) and viability and angiogenesis 
evidence in the engrafted region. The trial was originally designed to enroll 300 patients but 
was stopped early, with an intended enrollment of 120, after the data safety and monitoring 
board	determined	that	the	study	was	unlikely	to	show	a	benefit	of	treatment.	Ultimately,	only	
97 patients with ischemic heart failure were actually randomized at 24 European centers. The 
low-dose	group	(n=33)	received	approximately	400	x	106	myoblasts	delivered	to	30	locations	
within	and	around	the	infarct	site	during	the	CABG	procedure;	the	high-dose	group	(n=30)	re-
ceived 800 X 106 cells. Placebo group consisted of 34 patients. All the patients were implanted 
an ICD. 3 patients died after the cell transplantation and two randomized patients died awaiting 
the surgery without cell implantation. None of the deaths were considered to associate with the 
myoblast transplantations. LVEF was increased by 3% in the high-dose patients, compared to 
a	2%	increase	in	the	low-dose	arm,	and	no	change	in	the	placebo	arm	(p=0.04	for	high-dose	
compared	to	placebo;	p=ns	for	low-dose	compared	to	placebo).	Also,	LV	end-diastolic	volume	
was	significantly	improved	in	the	high-dose	arm	compared	to	placebo	(p-0.006),	but	not	in	the	
low-dose arm. LV end-systolic volume decreased by 18% in the high-dose patients, compared 
with	a	3%	reduction	in	the	placebo	patients	(p=0.008).	The	investigators	concluded	that	feasi-
bility of autologous myoblast grafting was demonstrated. There were no serious adverse events 
in	the	high	or	low	dose	myoblast	groups.	There	was	an	absence	of	significant	improvement	in	
regional or global contractility, but some evidence for reversal of remodeling.
CAUSMIC (First United States Randomized Controlled Trial Utilizing 3-Dimensional 
Guided, Catheter-Based Delivery of Autologous Skeletal Myoblasts for Ischemic Cardiomy-
opathy)- study was presented by Dib in the American College of Cardiology 56th annual meet-
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ing in 2007 (Dib and others 2007). It  showed improvement in NYHA class in the myoblast 
transplanted patients. A total number of 23 patients were enrolled in a randomized, but not 
blinded assessment had transendocardial injections of 30 – 600 x106 myoblasts performed with 
the NOGA system. The primary endpoints included feasibility and safety of the NOGA trans-
plantation	method.	The	functional	efficacy	was	assessed	by	quality	of	life	measures	(NYHA	
class and Minnesota living with heart failure questionnaire), the viability by NOGA electro-
mechanical mapping, and the function by echocardiography. Inclusion criteria consisted of 
previous heart failure, a nonviable scar and heart failure with a NYHA class II-IV. There was 
a	significant	 improvement	 in	 the	NYHA	class	 in	 the	myoblast-transplanted	patients,	but	not	
in the control group of maximal medical treatment. There was a suggestive decrease in the 
ventricular volumes in the myoblast-transplanted patients, when the volumes increased in the 
control patients.  According to the presented data, FDA approved a larger phase II randomized, 
double-blind, placebo-controlled multicenter study of 160 patients. 
Ventricular arrhythmias after  
the myoblast transplantation
Episodes	of	ventricular	tachycardia	and	fibrillation	have	been	noted	after	the	myoblast	trans-
plantation procedure. Because the studies in humans so far has boon non-randomized, the 
patient populations have been small and the heart disease has arrhythmogenic nature itself, it 
is	difficult	to	show	the	direct	causality.	Anyhow,	in	the	study	of	menasche,	4	out	of	10	patient	
had sustained ventricular tachycardia and had ICD implanted (Menasche and others 2003). 
Furthermore, in the study of Smits et al., one patient died suddenly 9 days post procedure. 
Another patient (ICD patient) survived an electrical storm 12 days post procedure, but died 2 
days later due to cardiogenic shock. Two other non-ICD patients received an ICD because of 
observed ventricular arrhythmias (Smits and others 2006). It remains unknown whether these 
events are directly related to the cell injections. In the MACIC-trial there was considered no 
myoblast	associating	significant	arrhythmogeninity	(Menasche	and	others	2008a)	and	in	the	
FDA-approved forthcoming study planned by Dib et al., no prophylactic ICD implantation is 
needed (Dib and others 2007).
End-stage coronary artery disease
Coronary artery disease (CAD) is a leading cause of death in the western world (Rosamond and 
others 2008). Despite advances in the pharmacological and interventional treatment, a portion 
of the patients have diffuse coronary disease with small distal vessels unsuitable for interven-
tion	with	significant	symptoms	with	maximal	medical	therapy.	In	the	western	world,	when	the	
population ages, the amount of these patients may increase (Mukherjee and others 1999). 
End-stage	coronary	artery	disease	is	defined	as	persistence	of	angina	pectoris	symptoms	
class III and IV despite maximally tolerated conventional medical treatments and ineligible 
coronary arteries to conventional revascularization procedure. The function of the LV should 
be normal or near normal. Pharmacological treatment should be based on the three mainstays: 
nitrates, betablockers and calcium antagonists. Also a recent angiogram should be evaluated 
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to avoid withholding a possible CABG or PCI (Schoebel and others 1997). Alternative means 
of	improving	blood	flow	to	the	heart	in	these	patients	should	be	developed.		Novel	approaches	
in patients who have end-stage coronary artery disease should decrease anginal symptoms and 
increase functional capacity. Also increased life expectancy would be desirable. 
Several alternative approaches to end stage coronary heart disease have been introduced. 
Intermittent urokinase therapy has been introduced as an anticoagulant approach. A dose of 
500 000 international units three times a week for a period of 12 weeks decreased symptoms 
70% compared to a control group of smaller dose (Leschke and others 1996). The possible 
mechanism of action was proposed to be dependent of rheological blood properties mediated 
by	fibrinogen	reduction,	thrombolysis	of	non-occlusive	subclinical	thrombi,	and	regression	of	
atherosclerotic plaques. In neuromodulation stimulation of vibratory efferent nerves or spinal 
cord would be effective in relieving angina pectoris symptoms (Mannheimer and others 1982). 
Several studies demonstrated improved symptom control, reduced nitrate usage, increased ex-
ercise tolerance and extended walking times to ischemia in CAD (Moore and Chester 2001). 
The nature of the treatment makes it rather impossible to randomize the treatment of the pa-
tient,	and	the	placebo	effect	is	difficult	to	rule	out.	
External enhanced counterpulsation (EECP) is based on a system, where compressed air is 
conducted to cuffs wrapped around patients lower extremities in a sequence synchronized with 
the cardiac cycle (Arora and Shah 2006). The EECP has claimed to improve symptoms and 
decrease long-term morbidity via several mechanisms, including improvement in endothelial 
function, promotion of collateralization, enhancement of ventricular function, improvement in 
oxygen consumption, regression of atherosclerosis, and peripheral training effects similar to 
exercise	(Manchanda	and	Soran	2007).	The	first	randomized	study	of	EECP	was	presented	by	
Arora et al (Arora and Shah 2006). In this study, CAD patients were randomized with similar 
patient group with similar non-effective pulsation system. EECP reduced angina in the treat-
ment group and extended time to exercise-induced ischemia in patients with enhanced external 
counterpulsation. Recent evidence also suggests that ECCP may be applicable also for heart 
failure. 
Transmyocardial (laser) revascularization (TMR) has been studied extensively. This tech-
nique consists of mechanical force to create small holes through the left ventricular wall. In a 
non-randomized multicenter trial of 200 end stage coronary patients with a sole therapy of TMR, 
the treatment provided angina relief, decreased hospital admissions, and improved perfusion 
assessed by single photon emission computed tomography. The procedure was performed via 
left anterolateral thoracotomy and perioperative mortality was 9% (Horvath and others 2005). 
All in all, six prospective randomized clinical trials have been performed with transmyocardial 
laser revascularization (Aaberge and others 2000; Allen and others 1999; Burkhoff and oth-
ers	1999;	Frazier,	March,	Horvath	1999;	Jones	and	others	1999;	Schofield	and	others	1999).	5	
studies out of 6 have been performed using percutaneous method. All of the transmyocardial 
laser revascularization and 4 of the percutaneous myocardial revascularization studies showed 
a	significant	improvement	in	angina	class.	The	results	concerning	improved	survival,	increased	
exercise	tolerance,	enhanced	LVEF,	and	improved	myocardial	perfusion	were	less	definitive.	It	
has	been	stated,	that	TMR	would	have	significant	potential	for	morbidity	and	mortality	(Tasse	
and Arora 2007). In the recommendations of the Society of Thoracic Surgeons for use of TMR 
(Edwards and Ferguson 2004), it is recommended as a sole therapy for patients with an LVEF 
22
greater than 30% and CCSAS class III or IV angina that is refractory to maximal medical 
therapy, in the case when reversible ischemia of the left ventricular free wall is not amenable 
to revascularization. In a database study of 3,717 patients, mortality rate of 6.4% for TMR as a 
sole therapy was observed. Operative risks were higher among patients with recent myocardial 
infarction, low LVEF and unstable angina was observed (Peterson and others 2003).
Cardiac transplantation provides best results for end-stage coronary artery disease, but graft 
shortage is a worlwide dilemma. Furthermore, the patients are often old and thus beyond trans-
plantation programs. 
Porcine models for coronary artery disease
Different species has been used in an attempt to produce an animal model imitating human 
occlusive coronary artery disease. These models have been produced to study the physiological 
changes in heart in a condition of inadequate coronary blood supply. The physiological changes 
include effort ischemia, collateral vessel formation, hibernation, stunning, and microvessel dys-
function (Hughes and others 2003). Chronically stunned myocardium describes myocardial re-
gions	with	persistent	dysfunction	despite	normal	basal	coronary	blood	flow	(Fallavollita,	Perry,	
Canty 1997a; Fallavollita, Perry, Canty 1997b). This phenomenon of persistent postischemic 
dysfunction is considered to be a derivative of repetitive episodes of stress-induced ischemia in 
a	state	of	insufficient	coronary	flow	reserve.	In	the	case	of	hibernation,	there	is	persistent	myo-
cardial	dysfunction	with	insufficient	coronary	flow	at	rest.	Although	these	phenomena	can	be	
observed	distinct,	even	so	that	specific	characteristic	structural	alteration	can	be	distinguished,	
in clinical situation there is much overlapping (Hughes and others 2001a). In a study compar-
ing pre-existing collateral vessels between different mammalian species, a wide spectrum of 
pre-existing collateral network was demonstrated to exist between various mammalian species 
(Maxwell, Hearse, Yellon 1987). This study showed, that porcine heart has very sparsely ar-
ranged collaterals in the case of non-ischemic heart, similar to human. Conversely, this study 
demonstrated that the dog, which has been commonly used species in studies of myocardial 
ischemia, has a variable and often substantial collateral circulation network. These existing 
small	vessels	are	able	 to	provide	up	 to	40%	of	normal	flow	to	 the	myocardium	distal	 to	an	
acutely occluded coronary artery. As a result, the porcine gained popularity as species in coro-
nary disease modelling. Furthermore, the comparison of macroscopic anatomy of porcine to 
human heart has showed great similarity, especially the coronary anatomy (Crick and others 
1998a).
There	has	been	several	different	methods	of	producing	impaired	coronary	flow	in	ischemic	
porcine models. The Ameroid constrictor model has been the most used model of chronic 
ischemia. The Ameroid constrictor consists of a slowly swelling plastic ring enclosed in metal 
cover. The plastic ring is shaped of formaldehyde dried milk casein, which slowly absorbs 
water. When applied around an artery, the metal cover forces the plastic to swell towards the 
vessel. Vessel occlusion ensues within following weeks, although somewhat imprecise occlu-
sion	has	been	documented.	Other	methods	include	use	of	fixed	stenosis	(Chen	and	others	1997;	
Fallavollita, Perry, Canty 1997a; Fallavollita, Perry, Canty 1997a; Lai and others 2000) and 
hydraulic occluder (Bolukoglu and others 1992).
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Porcine has also similarity in cardiac physiology compared to human, with the distribution 
of the coronary artery blood supply, including a typically right-dominant coronary system. 
Also the cardiac conduction system is very similar to humans (Swindle and others 1986). Like-
wise, the heart size-to-body weight ratio (0.005) for the typical 30-kg pig used in most labora-
tory studies is identical to that of humans (Hughes 1986). Finally, the swine heart is similar to 
that	of	humans	from	a	metabolic	standpoint	as	well.	Principally	nonesterified	fatty	acids	are	the	
main substrate under non-ischemic accounting for up to 80% of myocardial energy production 
(Abdel-Aleem	and	others	1999).	During	ischemia,	the	β-oxidation	of	fatty	acids	reduces,	and	
the use of glucose increases.  
Therapeutic angiogenesis
Therapeutic angiogenesis is an experimental concept for the treatment of ischemia of an end-
organ due to occlusive vascular disease. It involves activation of vessel growth in a situation, 
when conventional revascularization procedures are not amenable. Three different processes 
may involve in the growth of the new blood vessels: vasculogenesis, arteriogenesis, and ang-
iogenesis (Ferrara and Alitalo 1999; Ware and Simons 1997). Vasculogenesis is the process of 
vascular development during embryogenesis (Beck and D’Amore 1997). Arteriogenesis refers 
to the growth of vessels containing all the three layers of the artery wall. Arteriogenesis is 
dependant of shear forces, and the substrates of arteriogenesis are pre-existing collateral arteri-
oles. Angiogenesis is the process of formation of new small capillaries consisting of endothelial 
cells (Ware and Simons 1997). The process of blood vessel growth occurs in a wide spectrum 
of	 different	 physiological	 and	 pathophysiological	 processes.	 Inflammation,	 tissue	 ischemia,	
hypertrophy, and wound healing are among other biological states, when new blood vessel 
growth has been shown to develop. 
Several biologic mechanisms has been described as causal to arteriogenesis, such as en-
dothelial cell activation, basal membrane degradation, leukocyte invasion, proliferation of vas-
cular cells, neointima formation, changes of the extracellular matrix and cytokine participation 
(Cai and Schaper 2008). New capillaries form by sprouting or by splitting of the pre-existing 
vessels. Sprouting angiogenesis forms entirely new vessels differently from splitting angiogen-
esis. In splitting angiogenesis the capillary vessel extends into neighbouring vessel splitting it 
in two. Splitting angiogenesis is reorganization of the existing structures. It is also called intus-
susception (Folkman 1995; Risau 1997). 
The ideal agent for therapeutic angiogenesis should have a potent effect and it should be 
spesific	 for	 the	 target	organ	or	 tissue,	with	sustained	clinical	benefit.	Administration	should	
be feasible and non-invasive (Emanueli and Madeddu 2006).  It should maintain a high local 
concentration and adequate exposure time. Although some drugs show pro-angiogenic effect 
(Schaper 2005), so far only biological agents have been used to provide angiogenic therapy. 
There are three major ways to promote angiogenesis: protein therapy, gene therapy and cellular 
therapy (Al Sabti 2007).
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Gene therapy for coronary disease
The argument supporting gene therapy as a method for therapeutic angiogenesis holds that gene 
therapy can overcome the short half-life of the angiogenic proteins by generating a prolonged 
local protein expression (Lopez and others 1998). Stimulation of vessel growth in heart by gene 
therapy has been under preclinical and early phase I-II clinical investigations over a decade 
(Edelstein	and	others	2004).	Research	studies	have	identified	various	angiogenic	growth	fac-
tors that can enhance new blood vessel formation. Studies in animal models have shown great 
potential of angiogenic gene therapy to treat myocardial ischemia. The results of clinical trials 
with gene therapy to enhance growth factor production have been disappointing, showing only 
mild improvements. To date, therapeutic angiogenesis remains at an early stage of development 
(Ahn and others 2008).
Vectors for gene therapy
Gene transfer can be can be performed by non-viral systems and recombinant viral techniques. 
The non-viral systems include plasmids and oligonucleotides and their derivatives. A growing 
number of vectors have been developed and are available for experimental and clinical gene 
transfer experiments (Dulak and others 2006). A substantial portion of the gene therapy proto-
cols has been based on plasmids or short-strand nucleid acids, which are delivered through cell 
membrane in naked form or with the help of various chemical or physical methods. Because of 
the possible negative effect to a cell from the foreign nucleotide sequence, it is logic to assume 
that one of the main tasks of the cell membrane is to protect the cell from such invasion. The 
efficacy	of	the	naked	DNA	transfection	and	the	resulting	gene	expression	is	low	and	transient,	
lasting only for 1-2 weeks (Yla-Herttuala and Alitalo 2003). However, plasmids avoid many 
of the biosafety concerns associated with viral techniques. Plasmids are also easy to produce 
(Verma and Weitzman 2005). 
The adenoviral DNA vector is a plasmid DNA that contains a portion of the viral genome. 
Recombinat adenoviral vectors contain several advantages for cardiac gene transfer. Since ad-
enoviral replication depends on certain region of the viral genome, all recombinant adenoviral 
vectors	have	this	region	of	its	genome	deleted,	and	are	replication-deficient.	These	vectors	are	
capable of infecting a cell only once, no viral propagation occurs, and the infected cell does not 
die as a result of vector infection. Viral entrance through cell membrane occurs via receptors, 
and the formed endosome release viral capsid. Nuclear entry of the viral DNA is completed 
upon capsid dissociation, and the viral DNA does not integrate into the host genome but re-
mains in an episomal state. These viruses can be prepared in extremely high titers and they 
are able to infect both replicating and non-replicating cells. The production is relatively sim-
ple.	Adenoviruses	have	shown	to	confer	efficient	transduction	of	cardiomyocytes	after	direct	
injection or perfusion approaches (Svensson and others 1999). Human recombinant adenoviral 
vectors have been the most used viral vectors in pre-clinical gene therapy models as well as 
in clinical gene therapy studies. The main disadvantage of the adenoviral gene therapy is the 
capacity	to	evoke	intense	immune	and	inflammatory	reaction	in	the	host	(Edelstein	and	others	
2004). In animal models, adenoviral vectors have been reported to cause myocardial and vas-
cular	inflammation,	endothelial	cell	dysfunction,	vasoproliferation	and	intravascular	thrombus	
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formation. The death of a young human subject in a clinical trial conducted by adenoviral gene 
transfer has aroused the appreciation of the possibility of serious adverse events (Isner and 
others 2001). The other disadvantages of the adenoviral vectors include transient gene expres-
sion in animal models the cardiac gene transfer by adenovirus has generated a high-level gene 
expression of approximately one week. The duration of the transgene expression may improve 
in	 systems	using	 cardiac	 specific	promoters.	Additional	 constraint	 for	 adenoviral	 use	 is	 the	
possible pre-existing neutralizing antibodies of the host and possible de novo development of 
antibodies to inhibit the re-administration of the same serotype. 
Recombinant adeno-associated viruses (AAV) are derived from non-pathogenic parvovi-
ruses.  AAVs require cells to be doubly infected by a helper virus to replicate in nature. There 
are 11 serotypes of AAVs.  Many of these serotypes have been shown to be effective in gene 
transfer (Chen and others 2005; Denby, Nicklin, Baker 2005; Nicklin and others 2001). The ad-
vantages of the AAV include the apparent lack of cellular immune response, the low immuno-
genicity depend on neutralizing antibodies. In comparison with adenoviral gene transfer, car-
diac injection of recombinant AAV vectors produces less initial, but more sustained transgene 
expression. AAV can infect non-dividing as well as dividing cells and has the ability to stably 
integrate	into	the	host	cell	genome	(Gaffney	and	others	2007).	There	is	a	specific	site	in	the	
human 19th chromosome, where most of the AAVs DNA integration takes place (Young and 
others 2000). This is an advantage compared to the retroviruses, which present a random inser-
tion	and	thus	the	possibility	of	mutagenesis.	Whether	the	expression	level	and	the	efficiency	
produced	by	AAV	in	cardiac	diseases	will	be	sufficient,	remains	to	be	seen.	AAVs	have	spesific	
tropisms,	altering	of	which	might	allow	efficient	targeted	vector	(Bartlett	and	others	1999).		
Lentiviruses are derived from the family of retroviruses (Totsugawa and others 2002). The 
infection of cells by retrovirus is mediated by attachment of the viral envelope glycoprotein 
to the target cell-surface receptors. The RNA genome is converted to DNA by reverse tran-
scriptase and eventually integrated to host genome (Sakoda and others 1999). This integration 
results in stable, prolonged, and potentially high expression of the therapeutic transgene, de-
pending on integration site. The most characterized lentiviral vector system is based on the hu-
man	immunodeficiency	virus	type	1	(HIV-1)	(Rebolledo	and	others	1998).	Only	low	titres	are	
achievable at present and safety concerns regarding random insertion of reverse-transscripted 
DNA into the host genome are current drawbacks. Lentiviruses are able to transduce also non-
dividing cells (Frimpong and Spector 2000). 
Angiogenic receptors and factors
The VEGF- family consists of various members of the VEGF family having overlapping abili-
ties to interact with a set of cell-surface receptors, which trigger responses to these factors 
(Yancopoulos and others 2000). The main receptors that seem to be involved in initiating signal 
transduction cascades in response to the VEGFs, comprise a family of closely related receptor 
tyrosine kinases consisting of three members now termed VEGFR-1, VEGFR-2 and VEGFR-3. 
In addition, there are a number of accessory receptors such as the neuropilins, which seem to 
be involved primarily in modulating binding to the main receptors (Soker and others 1996; 
Soker and others 1998). Mice lacking VEGFR-1 seem to have excess formation of endothe-
lial cells which abnormally coalesce into disorganized tubules (Fong and others 1995), but 
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when the animals were engineered to express VEGFR-1 lacking its kinase domain appeared 
rather normal (Hiratsuka and others 1998). These data suggested a regulator role of decoy 
or ligand-binding supressor of VEGFR-1. Partial blockage of VEGFR-2 during development 
of VEGFR-1 resulted in less pathologic vasculature (Roberts and others 2004). There is also 
evidence	of	VEGFR-1	mediated	pathological	angiogenesis	and	inflammation	(Carmeliet	and	
others 2001). Furthermore, there is evidence of VEGFR-1 mediated suppression of proapop-
tocic gene expression (Li and others 2008). VEGFR-2 seems to mediate the major growth and 
permeability actions of VEGF. Mice engineered to lack VEGFR-2 fail to develop a vasculature 
and have very few endothelial cells (Carmeliet and others 1996). VEGFR-1 shows at least a 10-
fold	higher	affinity	to	VEGF	of	only	the	extracellular	domain,	but	about	a	10-fold	lower	kinase	
activity than VEGFR-2 (Hiratsuka and others 2001; Sawano and others 1996; Sawano and 
others 1997; Shibuya 1995). On the other hand, VEGFR-3 is responsible for the development of 
lymphatic vessels (Dumont and others 1998a; Iljin and others 2001; Taipale and others 1999). 
Mice, which lacked a functional VEGFR-3 gene showed defective blood vessel development in 
early stage mouse embryos (Dumont and others 1998b). Thus, the signalling through VEGFR-3 
has an essential role not only for lymphatic vessel formation but also for angiogenesis. Neuropi-
lin	receptors	1	and	2	regulate	neuronal	guidance	and	they	bind	to	VEGF	in	an	isoform	spesific	
manner (Fujisawa and others 1997; Fujisawa and Kitsukawa 1998). In the endothelial cells 
neuropilins function as a supplementary receptors, regulating and enhancing the signalling of 
the VEGFs (Gluzman-Poltorak and others 2000; Karkkainen and others 2001).
Most of the research on the VEGF family so far, especially with respect to the angiogen-
esis, has focused on VEGF-A, which has different isoforms (Yla-Herttuala and Alitalo 2003). 
VEGF-B binds to both VEGFR-1 and neuropilin-1. VEGF-B is implicated in angiogenesis by 
its role in the regulation of extracellular matrix degradation, cell adhesion and migration of 
endothelial cells (Olofsson and others 1998). VEGF-C is a ligand for both VEGFR-2 and VEG-
FR-3 (Joukov and others 1996).  VEGF-C is synthesized as a prepropeptide and subsequently 
undergoes proteolytic maturation. Only the fully processed form is able to activate VEGFR-2 
(Joukov and others 1997).  VEGF-D is structurally very similar to VEGF-C and it also binds to 
VEGFR-2 and VEGFR-3 (Achen and others 1998). VEGF-D is mitogenic for endothelial cells 
and thus may play a role in endothelial cell regulation. The expression of VEGF-D is promi-
nent in heart and skeletal muscle. VEGF-E is the collective term for a group of proteins with 
homology to VEGF-A that are encoded by certain strains of the orf parapoxvirus (Robinson 
and Stringer 2001). It possesses about 25% amino acid identity to mammalian VEGF (Lyttle 
and others 1994). 
Fibroblast growth factors (FGFs), have profound effects in various endothelial cell assays, 
but	are	also	known	to	be	nonspecific	in	that	they	could	act	on	many	other	cell	types	(Colvin	and	
others 2001; Ellman and others 2008; Kapur and Rade 2008; Ornitz and Itoh 2001). The FGF 
family	is	a	large	group	of	proteins,	which	share	30−70	%	identical	primary	sequences.	Of	these,	
FGF-1, FGF-2, FGF-4 and FGF-5 have been used for angiogenesis studies (Javerzat, Auguste, 
Bikfalvi 2002). HGF is also a potent mitogen of endothelial cells and it also activates many 
other types of cells as well and has thus cardioprotective properties (Ono and others 1997). 
In	addition,	many	other	growth	factors	that	are	not	vascular	endothelium-specific	are	also	re-
quired for blood vessel formation, such as members of the platelet-derived growth, although 
these factors also have critical roles for many other systems as well (Zhang and others 2008).
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Administration strategy for Angiogenic Therapy
Local gene delivery to the target organ should be prefered, when optimal treatment-effect ver-
sus	side-effect	profile	is	aimed	(Simons	and	others	2000).	Percutaneous	delivery	methods	are	
readily available due to the wide spread catheterization techniques in cardiology. The gene 
material can be injected directly into coronary circulation under angiographic inspection. Di-
rect intramyocardial injection technique is possible via percutaneous route if special catheters 
are	passed	through	aortic	outflow	track	into	LV	(Kastrup	and	others	2005;	Rutanen	and	others	
2004a). Venous cathetrization enables the use of coronary sinus. With a special side needle the 
therapy can be injected through veins into the myocardium (Siminiak and others 2006). Gene 
therapy can also be delivered from stents using cellular basesd techniques (Koren and others 
2006). During surgery as a concomitant procedure, the injection can be easily performed, but 
as a solitary procedure the injection itself causes risks and burden to the patient.   
Side effects of the angiogenic treatment
The disadvantages of gene therapy are dependent in the vector used, gene transducted and the 
route of the delivery of the treatment. In any case, introduction of foreign genetic material can 
be considered as a potential risk. The exposure to the vector, especially when viral vectors are 
used	might	possess	risks	due	 to	 inflammatory	response	(Isner	and	others	2001).	 Inability	 to	
regulate the gene expression might possess risk, at least in case of overdose in targeted (Lee 
and others 2000b; Schwarz and others 2000; Springer and others 1998) or non-targeted tis-
sues, especially in case of malignancy (Folkman 1971), or retinopathy (Aiello and others 1994; 
Miller and others 1994). Some angiogenic factors have also shown to accelerate atherosclerosis 
(Celletti and others 2001; Inoue and others 1998) and cause odema (Dvorak and others 1999; 
Senger and others 1983). The uncontrolled insertion of the viral-originated DNA of retrovi-
ruses to the host genome might cause carcinogenic effect (Duesberg 1987).
Human trials for therapeutic angiogenesis in  
coronary disease
In a trial, 6 patients were receiving naked plasmid VEGF-C by transmyocardial injections via 
percutaneus catheter. The VEGF-C transfected patients experienced reduced angina, reduced 
nitroglycerin consumption and reduced ischemia by electromechanical mapping as well as my-
ocardial perfusion by SPECT-sestamibi scanning for up to 90 days after GTx when compared 
with images obtained after control procedure (Vale and others 2001)
In a non-randomized phase I multi-center trial 30 patients Class III or IV angina refrac-
tory to medical therapy were enrolled to receive intramyocardial injections of VEGF-C in a 
dose-escalating fashion. The procedure was performed via a mini-thoracotomy. Patients were 
followed for clinical events after one year by hospital records, follow-up visits or telephone 
contact. At the most recent follow-up, no patients had Class IV angina, and only three (11.5%) 
had Class II angina, while the remaining had Class I or II angina. Compared to baseline, aver-
age	angina	class	decreased	from	3.6	±	0.5	to	1.3	±	1.0	after	the	first	year.	This	benefit	persisted	
to 24 months when the mean angina class was 1.5 ± 1.2 (p< 0.05). Major clinical events such 
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as death, myocardial infarction (MI, or heart attack) and repeat revascularization were uncom-
mon	during	the	first	year	but	more	frequent	after	one	year	at	a	rate	consistent	with	the	severity	
of the underlying disease in a population with advanced atherosclerosis. The majority of events 
were the result of progression of disease in areas of the heart remote from the site of injection 
(Reilly and others 2005).
In VIVA trial, a total of 178 patients with coronary artery disease were randomized to 
receive high or low dose of recombinant VEGF-A165 protein or placebo. The protein or treat-
ment was infused intracoronary route. The primary end point was treadmill exercise capacity 
at	4	months.	There	was	no	significant	difference	between	the	groups,	anyhow	the	high	dose	
VEGF-A	 improved	 significantly	 in	 angina	class	 as	 compared	 to	placebo	 (Henry	and	others	
2003). 
The	KAT	(Kuopio	Angioplasty	phase	II)	Trial	 investigated	the	efficacy	of	 intracoronary	
plasmid/liposome VEGF-A165, adenoviral VEGF-A165 or placebo injection in conjunction 
with coronary stenting procedure. Primary end point included restenosis and myocardial per-
fusion at 6 months. Restenosis was similar between the groups, but adenoviral VEGF-A165 
group showed improved perfusion at the end of the study (Hedman and others 2003). 
In a study conducted by Losordo et al., 19 patients were randomized to percutaneous in-
tramyocardial catheter delivered naked VEGF-C plasmid in three different doses or placebo. 
Patients	receiving	VEGF-C	plasmid	showed	significant	reduction	in	angina	class	at	12	months	
(Losordo and others 2002). 
In the EUROINJECT One-study, a total of 80 patients were recruited to receive either 
naked plasmid VEGF-A165 or placebo by percutaneus intramyocardial injections as a sole 
therapy. At 3 months, there was no difference between the groups assessed by the size of the 
perfusion defect or CCS class. However, catheter based mapping of the left ventricular motion 
at the injection site was better in the treatment group, when compared to the placebo group 
(Kastrup and others 2005). 
In the REVASC (Randomized Evaluation of VEGF for Angiogenesis in Severe Coronary 
Disease) trial, 67 patients were randomised to either maximal medical therapy or to receive ad-
enoviral VEGF-A121 with intramyocardial injections by open thoracotomy. At 3 months after 
randomization, there was no difference between the groups, but at 6 months in the adenoviral 
VEGF-A121	group	exercise	test	was	significantly	improved	(Stewart	and	others	2006).	
In the GENASIS trial a total of 295 patients, who were not suitable for traditional revascu-
larization procedures were enrolled to receive naked plasmid VEGF-C or placebo. The treat-
ment was given by intramyocardial injections with a percutaneous catheter. The primary ef-
ficacy	endpoint	in	the	GENASIS	clinical	trial	was	an	improvement	of	at	least	one	minute	in	
exercise tolerance time from baseline to three months. The primary endpoint showed no statis-
tical difference between the groups. The data indicated considerable overlap in results between 
the treatment and placebo groups for the secondary endpoints as well, and no clear dose effect 
was seen.
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4. Aims of the present study
The main purpose of this study was to assess cell proliferation methods in treating ischeamic 
heart disease in porcine model by using MRI, PET and SPECT.
Specific Aims:
1.  Testing the angiogenic potency of ad-VEGF-C administered intramyocardially (I)
2.  Improving the Ameroid occlusion in model of myocardial ischaemia by time-adjusted 
 ligation of the stenosed vessel (II)
3.  Assessing spontaneous regeneration in ischeamic-infarcted porcine heart in terms of cellular 
 proliferation, perfusion and angiogenesis (II-III)
4.		 Assessing	 the	 efficacy	 of	 autologous	 myoblast	 transplantation	 in	 ischemic/infarcted	 
 porcine heart (IV)
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5. Materials and Methods
Agreements and notifications
The Local Ethics Committee of Helsinki University Central Hospital and the Provincial State 
Office	of	Southern	Finland	approved	all	animal	experiments	and	notification	was	submitted	to	
the Board for Gene Technology. 
 
Treatment and anaesthesia of the animals 
Landrace piglets were used as laboratory animals to provide a model of coronary heart disease. 
Fifteen animals (weight 17-27kg) was used in study I, 11 animals (weight 18-26kg) in study II-
III and 44 animals (weight 18-26kg) in study IV. All animals were maintained and treated in 
accordance with the “Principles of Laboratory Animal Care” formulated by the National So-
ciety for Medical Research and the “Guide for the Care and Use of Laboratory Animals” pre-
pared by the National Academy of Sciences and published by the National Institutes of Health 
(NIH publications No. 86-23, revised 1985). General anaesthesia was induced in the animals in 
a fasting state by intramuscular azaperone (4-8 mg/kg), ketamine hydrochloride (5 mg/kg) and 
atropine sulfate (0.05mg/kg). They were intubated and ventilated with Siemens Servo ventilator 
900C (Siemens Elema AB, Solna, Sweden). Anaesthesia was maintained with additional bo-
luses of intravenous ketamine hydrochloride (50-100 mg) and continuous infusion of propofole 
(4-12mg/kg/h). In the case of operative procedures, pancurone (0.1 mg/kg) was used for muscle 
relaxation and fentanyl (0–5 µg/kg) for pain management. In that case, prophylactic intramus-
cular ceftriaxon 500 mg and intravenous ranitidine 25 mg were given. Postoperative pain was 
treated with intramuscular diclophenac acid (25-37.5mg).
The study implementation 
Ameroid model of myocardial ischaemia (Study I-IV)
A left thoracotomy was performed anterolaterally at the level of 4th intercostal space. Pericar-
dium was incised and the left auricle was displaced. Epicardium was incised over the proximal 
left	circumflex	artery	(LCx)	just	after	the	bifurcation	of	the	left	main	coronary	artery.	If	the	
animal	exhibited	trifurcation	of	the	left	main	coronary	artery	i.e.	a	significant	left	intermediate	
coronary branch was apparent, the animal was discarded from the study. The proximal LCx 
artery was dissected free and an Ameroid constrictor with an internal diameter of 2.5 mm 
(manufacturer: Research Instruments SW, Escondido, CA, USA) was placed around the LCx. 
The wound was closed with synchronous lung expansion to minimize the amount of pneumot-
horax and the animal was allowed to recover.
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Administration of adVEGF-C and adLacZ vectors (Study I)
At three weeks after the Ameroid placement, re-thoracotomy was performed at the 5th inter-
costal	space.	The	lateral	wall	of	the	LV	was	exposed.	A	partial	resection	of	the	fifth	rib	was	per-
formed, if needed to receive adequate exposure. Adenoviruses encoding VEGF-C (adVEGF-C) 
or control beta-galactosidase (adLacZ) were injected directly into the myocardium as ten sepa-
rate 0.2 ml doses in the lateral wall of LV between LAD and LCx with 2x1011 viral particles 
(vp)	in	a	total	volume	of	2.0	ml	diluted	in	saline	with	a	2.0	ml	syringe	and	a	0.2	ml	Microflex	
infusion set (Laboratoires Pharmaceuticals Vygon, Ecouen, France). Prolene® purse-string 
suture was placed to encircle the area of the injections. The wound was then closed, and the 
animal was allowed to recover.  
Ameroid model with subsequent coronary ligation (Study II-IV)
After the pericardium was opened, and the Ameroid constrictor was positioned around the 
proximal LCx artery, a loose non-absorbable 3-0 band was applied around LCx artery. The 
thread loupe was placed just distally to the Ameroid constrictor, and the thread ends were con-
ducted via the third and fourth intercostal space and embedded in the muscular layer inside a 2 
cm long polyethene tube, which was cut from a needle holder. The wound was closed in three 
layers and the animal was allowed to recover. Two weeks (study IV) or three weeks (study II 
and III) later, another operation was performed. The plactic tube and the threads were exposed 
by dissecting through a separate skin incision. The loose band around LCx vessel was tight-
ened,	by	tying	the	threads	firmly	around	the	4th	costa,	and	the	wound	was	closed.	The	animal	
was	observed	for	one	hour	for	possible	arrhythmias	and	in	the	case	of	ventricular	fibrillation,	
electrical cardioversion was executed and if sinus rhythm was not reached, intravenous amio-
darone 5mg/kg was administered during re-cardioversions.
Myoblast harvest and transplantation (Study IV)
Two weeks after the Ameroid placement at the time of ligation procedure, skin was incised at 
the lateral thigh. A biopsy of 1cm3 was harvested from the lateral vastus muscle. The wound 
was sutured in layers. Muscle biopsy was eventually processed in the laboratory as described 
below. Two weeks later, after the pre-treatment cardiac assesment under general anaesthesia 
a thoracotomy was performed in the previous wound. The lateral free wall of the LV was ex-
posed	and	2	x	106	myoblasts	diluted	in	2	ml	of	Dulbecco’s	modified	Eagle	medium	(DMEM;	
Gibco-BRL Company, Grand Island, USA) were injected in the lateral wall of the LV. Injec-
tions were 0,2ml each applied over the free lateral wall of LV. Area of injections was encircled 
by a prolene® suture. 
Animal euthanasia and histological sampling (Study I-IV)
At the end of each study, animals were anaesthetized and euthanized with an overdose of 
potassium chloride. The tissue samples were collected from each heart. The animals in which 
the area of the treatment was marked with prolene® suture, the samples were collected from 
the marked area. In other animals a representative tissue sample of the LV lateral wall was 
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harvested. Another sample at the penumbra of the treatment area or representative area of the 
lateral wall was collected. Control samples were collected from each animal from the antero-
lateral septum of the LV.   
Preparation of the viral constructs and  
myoblast processing
Recombinant adenoviral vectors (Study I)
Adenoviral constructs encoding the complete human prepro-VEGF-C or nucleus-targeted LacZ 
were provided by Juha Rutanen (AIV-Institute, University of Kuopio). The constructs were 
prepared as described: “Cytomegalovirus (CMV) promoter was excised from the pcDNA3.1 
vector (Invitrogen), and a full-length human VEGF-C cDNA containing the 1997-bp sequence 
was excised from the previously constructed VEGF-C pREP7 expression vector. A human 
growth hormone polyadenylation signal was excised from an  -MHC gene promoter construct 
(a gift from Dr Jeffrey Robbins). The CMV promoter, VEGF-C cDNA, and the polyadenylation 
signal fragments were ligated into a pCRII vector (Invitrogen). The transcriptional unit was 
cloned into pAdenogal vector. This construct was then used to generate recombinant adenovi-
rus. VEGF-A (murine VEGF164) and nucleus-targeted lacZ adenoviruses were constructed in 
a	way	similar	to	that	previously	described.	Replication-deficient	E1-E3–deleted	clinical	GMP–
grade adenoviruses were produced in 293T cells.  Adenoviruses were analyzed to be free from 
helper viruses, lipopolysaccharide, and bacteriological contaminants.” (Hiltunen and others 
2000) 
Myoblast processing (Study IV)
Skeletal myoblasts were obtained from porcine vastus lateral muscle. Under sterile conditions, 
a	1cm3	muscle	sample	was	cut,	and	washed	twice	in	ice-cold	Ca2+-Mg2+	-free	Hank’s	bal-
anced salt solution (Gibco, Carlsbad, CA) containing antibiotics (100 IU/ml penicillin and 100 
µg/ml streptomycin). It was then carefully minced, and the fragments were enzymatically dis-
sociated by several incubations in serum-free DMEM, containing 0.25% trypsin and 1mg/ml 
type IV collagenase (Worthington, Lakewood, NJ). Between incubations, the fragments were 
further	dissociated	by	vigorous	pipetting.	Cells	were	then	filtered	from	the	digested	tissue,	were	
centrifuged 400 g for 10 minutes and washed twice in DMEM containing 10% fetal calf serum 
and antibiotics. The resulting cell suspension was plated for 45 minutes in uncoated plastic 25 
cm2	cell	culture	flasks	 to	remove	fibroblasts	by	the	differential	attachment	 technique.	Unat-
tached	cells	were	then	replated	on	cell	culture	flasks	coated	with	gelatin	(Sigma,	St	Louis,	MI).	
Cultures	were	incubated	at	37oC	in	a	humidified	atmosphere	of	CO2	(5%)	and	air	(95%).	After	
1 week in culture the cells were detached with trypsin and subcultured in 1:3–ratio. Three to 
four days after subculturing, the cells were collected for transplantation and staining. For trans-
plantation the cell-count was optimized to 1x106 cells/ml in serum-free DMEM. 
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Examination methods of the injured heart
Angiography (Study I-IV)
Coronary angiography was performed in vivo during anaesthesia just before the treatment 
(study I and IV) and four weeks thereafter. In the studies of spontaneous myocardial recovery 
from Ameroid induced stenosis and subsequent ligation (study II and III), angiography was per-
formed one and four weeks after the ligation. Siemens multistar T.O.P. angiography equipment 
(Siemens AG, Munich, Germany) was used with Hexabrix 200 mgl/ml contrast agent (Labora-
toire Guerbet, Roissy, France). Two observers blinded to treatment groups visually determined 
the	LCx	size	in		a	semiquantitative	manner	(1=	small,	2=normal,	3=large)	and	estimated	the	
percentage stenosis of the LCx. 
Schwartz	classification	was	used	to	grade	the	collateral	vessel.	In	this	classification,	the	fill-
ing of the stenosed vessel determines the function of the collaterals (Schwartz and others 1984). 
The	classification	is	divided	in	four	grades	(0-3).	Configuration	of	collaterals	were	divided	into	
three areas 1) antegrade collaterals locally around the Ameroid region, 2) the treatment area, 
which was the location of injections, 3) peripheral collaterals. The treatment area consisted of 
collaterals	from	the	first	branch	of	LAD	to	the	first	branch	of	LCx	or	peripheral	LCx	and	from	
the	second	branch	of	LAD	to	the	first	branch	of	LCx	or	peripheral	LCx	branches.	The	‘treat-
ment area index’ was calculated by change in number of visible collaterals between 3-week 
and 7-week studies in the treatment area divided by the change in collaterals in the entire left 
coronary area (study I). The Schwartz gradus and treatment area index were compared between 
groups. 
SPECT (Study I and II)
Technetium 99-m sestamibi SPECT was performed under general anaesthesia. Perfusion was 
assessed with the Toshiba GCA-7200A/UI dual head gamma detector (Toshiba Corp, Tokyo, 
Japan) with low energy high-resolution parallel hole collimators (NDCL-701A), 64x64 matrix, 
and a 20% window. Image acquisition was performed with 180-degree rotation and 30 stops 
at 20 seconds/stop. Electrocardiogram (ECG) was used to guide the acquisition, 16 frames 
between each R-R segment were obtained. Rest and stress imaging were performed for each 
animal with a minimum time interval of 4 hours between the tests. Rest imaging was assessed 
at a dose of 0.3 mCi/kg of 99mTc. Pharmacological stress was induced with a dobutamine in-
travenous	infusion	of	40	μg/kg/min,	the	dose	increasing	every	three	minutes	by	40	μg/kg/min	
up to 12 minutes, and an intravenous bolus of 0.3 mCi/kg 99mTc was given at 11 minutes. 
The SPECT images were processed with GCA-7200A/UI software (Toshiba). Multislice di-
agrams were automatically reconstructed from short axis slices. These diagrams were divided 
into 48 segments. The segment, which obtained most counts was assigned as a value of 100. 
Values of other segments were normalized to this segment. Global LVEF, regional wall mo-
tions, and cardiac volumes were supplied by the software. Left ventricular motion and thicken-
ing were acquired under stress separately, and presented as multislice diagrams on a ten-colour 
scale.  LV was divided into 13 segments in the motion and thickening multislice diagrams, of 
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which the four posterolateral segments represented the LCx perfusion area.  The mean motion 
or thickening in all the other segments was used as a control area measure. 
Image interpretation: Ejection fractions were calculated as the difference between end-di-
astolic and end-systolic volume divided by the end-diastolic volume. Improvement in LVEF un-
der stress was presented as percentage difference between rest and stress end-systolic volumes. 
90 degrees of circumferential count centred on the segment of maximal reversible ischaemia 
in a multislice diagram was determined to represent the LCx perfusion area in each image. 
Segmental counts in the whole LCx area were summed to reach a value representing both 
depth and extent of ischaemia. Apical segments were eliminated due to naturally low counts. 
Difference in counts between stress count sum and rest count sum at the LCx area presented 
the amount of reversible ischaemia.
PET (Study I and III)
Positron emission coincidence detection (CoDe) imaging was performed using dual-head coin-
cidence detecting gamma camera (Millenium VG-CoDe 5, GE Medical Systems, Milwaukee, 
WI, USA). This technology is based on a combined gamma camera and computed tomography, 
allowing all data gathering for attenuation in one imaging session (Bocher and others 2000). 
Fasting animals were anesthetised as described above. 25 g intravenous glucose and 6 IU of 
insulin	were	given	to	induce	an	insulin	clamp.	After	45	minutes,	3-4	mCi	of	18-fluorodeoxy-
fluoroglucose	(18F-FDG)	was	administered	intravenously	50	minutes	prior	to	imaging.	Images	
were acquired and multislice diagrams were reconstructed from attenuation corrected short 
axis slices. 
Analysis of the images was performed by a single observer blinded to randomisation. For 
each animal, the SPECT images were aligned for direct comparison. The level of 18F-FDG 
uptake at three weeks imaging in the LCx area was determined. In the study I, the change in 
18F-FDG uptake between 3- and 5-week images and between 5-and 7- week images in the LCx 
was determined as improvement or deterioration in collateral function. Results between any 
two	time-points	were	graded	in	a	semiquantitative	manner:	improvement	=	0,	no	change	=	1,	
deterioration	=	2.	Acquired	grades	were	compared	between	groups.	In	the	study	III,	90	degrees	
of circumferential count centred on the posterolateral portion of the LV was assigned as the 
lesion area. The mean count at the lesion area was compared to the mean count of the rest 270 
degrees of the multislice diagram.
Magnetic resonance imaging (Study III and IV)
Magnetic resonance imaging was performed with a 1.5 T Siemens Sonata scanner and a body 
array coil (Siemens AG, Erlangen, Germany). The animals were anestehetized and positioned 
supine. Long axis of the LV was imaged in two perpendicular planes. Short axis images were 
acquired with the three following MR sequences. Firstly, LV volume measurements and re-
gional wall thickening analysis were obtained by fast imaging with steady precession (True-
FISP) cine images. The sequence parameters were: Slice thickness 7mm, short axis sections 
7mm	apart,	temporal	resolution	33	ms,	300	cm,	matrix	256	pixels,	1.57	ms,	5.4ms	flip	angle	60°	
(Francois and others 2004). Secondly, to assess myocardial perfusion, an inversion recovery 
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turboflash	image	series	were	obtained	during	dipyridamole	stress	(Persantin®0.5	mmol/kg	in	
four minutes) and gadolinium- diethylenetriamine penta-acetic acid bolus injection (Magnev-
ist®, 0,10 mmol/kg). The four short axis planes were imaged repeatedly at every second for 
three	minutes	to	observe	the	myocardial	first	pass	of	the	contrast	agent.	The	sequence	param-
eters	were:	Slice	thickness	8	mm,	300	cm,	matrix	256	pixels,	0.99	ms,	183	ms,	flip	angle	8°	
(Sakuma and others 2005). 
Thirdly, the measure of infarct and viability, ten minutes after contrast injection, all long 
and short axis planes were imaged with an inversion recovery late enhancement sequence. The 
sequence	parameters	were:	slice	thickness	7mm,	field	of	view	300	cm,	matrix	256	pixels,	inver-
sion time 270 ms, time to echo 4.3 ms, time to repeat 750ms (Selvanayagam and others 2005).
Image analysis was performed with Impax Client software (Release 4.5, Agfa-Gevaert 
Group	NV,	Ridgefield	Park,	NJ)	in	study	III	and	IV,	and	Argus	software	(Siemens	AG	with	
Argus, Erlangen, Germany) in study IV. Left ventricular global and regional parameters were 
assessed	from	images	obtained	at	one	and	five	weeks	after	ligation.	Global	parameters,	LVEF	
and muscle mass, were assessed from short axis cine image series. The endocardial border was 
drawn at diastole and systole at each section. The LV cavity area was multiplied with the sec-
tion distance, and the global volumes were calculated as a sum of all short axis sections at end 
diastole and systole as end-diastolic volume (EDV) and end-systolic volume (ESV). EF was 
calculated as (EDV-ESV)/EDV. To obtain muscle area the epicardial border of each section 
was drawn. 
Wall thickening and perfusion of the ischemic LCx region at the free LV wall was com-
pared with the normal left anterior descendens (LAD) region at the anteroseptal wall on the 
short axis sections. Wall thickness at LCx region was measured at systole and diastole. The 
section with the smallest fractional thickening was selected to represent the ischemic area. The 
fractional thickening of LCx region was normalized to that of LAD region in the same section. 
Perfusion of the same LCx and LAD regions was observed from the contrast agent transit into 
the	myocardium	during	the	first	pass	imaging.	Perfusion	was	quantified	by	a	slope	of	pixel	in-
tensity increase versus time. The LCx slope was normalized to LAD. The amount of infarcted 
myocardium	was	 quantified	 from	 late	 enhancement	 images	 by	 dividing	 the	LV	 into	 the	 17	
segments according to AHA statement (Cerqueira and others 2002). Each segment was graded 
according	to	enhancement:	0	=	no	scar,	1	=	subendocardial	scar,	2	=	transmural	scar.	Relative	
amount of scar tissue was calculated by dividing summed scar units by total myocardial units 
of 34 (17 times 2 units). 
Short axis cine images were assessed for parameters of diastolic function. LV cavity time-
volume curves were acquired from data points of TrueFISP cine images. LV volume was meas-
ured	 throughout	 the	cardiac	circle.	Peak	filling	rate	 (PFR)	was	 the	maximum	rate	of	filling	
(ml/s)	between	two	frames	in	early	diastole.	Time	to	peak	filling	rate	(TPR)	was	the	time	(ms)	
from the end systolic frame to the time point of PFR. Duration of diastole (DD) was the time 
(ms)	of	the	cardiac	filling,	and	peak	ejection	rate	(PER)	was	the	maximum	rate	of	left	ventricu-
lar	emptying	between	two	frames	during	systole	(ml/s).	Early	diastolic	filling	was	the	volume	
change	of	LV	during	the	first	third	of	diastole.
36
Histological assessment (Study I-IV)
After above described studies the animals were euthanized and autopsied, the heart was re-
moved and the size and location of the infarction was macroscopically evaluated. In addition, 
tissue samples were collected for histological evaluation from the lesion area, from the border 
area and from the remote area of the myocardium. Hematoxylin-eosin staining was performed 
for	asssesment	of	infarction	and	inflammation.	
In order to detect the microvessels, immunohistochemistry was performed with von Will-
ebrandt factor antibodies (Rabbit Antihuman vWF, Code No A0082, Dako A/S, Glostrup, Den-
mark) and Vectastain® Elite ABC kit (Vector Laboratories inc, Burlingame, CA, USA) from 
adjacent	5-μm	sections	(studies	I-IV).	These	samples	were	analysed	under	a	light	microscope	
(Olympus Optical) by a single observer blinded to randomization. Microvessels were counted 
in	 three	randomly	selected	high-	power	fields	 in	 the	 treatment	area	and	from	apical	control	
area. The sample in each animal with the highest vessel density in the treatment area was con-
sidered to represent maximal microvessel development (study I-IV). Avidin-biotin-horseradish 
peroxidase with diaminobenzidine (DAB; Vector Laboratories inc, Burlingame, CA, USA) was 
used for immunohistochemistry of vascular smooth muscle (study I). Blood vessels were im-
munostained	with	a	mouse	monoclonal	antibody	against	α-smooth-muscle	antigen	(Clone	1A4,	
1:250 Sigma, St Louis, Missouri, USA)
The antibodies were polyclonal rabbit-anti-cyclooxygenase-2 (LabVision Corp., Fremont, 
CA, USA), monoclonal mouse-anti-desmin (Dako A/S, Klostrup, Denmark), monoclonal rabbit-
anti-Ki-67 (LabVision) and monoclonal mouse-anti-human macrophages (cross-reactive with 
pig macrophages, Serotech Ltd., Oxford, UK). With these, Ventana red alkaline phosphatase 
fast red detection kit was used (study IV).  For improved localization of proliferating nuclei, the 
sections	were	first	stained	for	cardiac	troponin-T	using	the	Ab-1	monoclonal	antibody	(Labvi-
sion, Fremont, CA, USA) and detection after incubation with alkaline phosphatase-conjugated 
secondary antibody (study IV). Thereafter the sections were double stained for Ki-67 using 
monoclonal rabbit-anti-Ki-67 (study IV). The number of dividing cells and dividing myocytes 
from adjacent sections stained for Ki-67, and troponin-T were counted by an experienced pa-
thologist blinded to the samples. The area of the sample on each slide was measured from with 
the PhotoShop software (Adobe Systems Inc., San Jose, CA, USA) after scanning. The density 
of the proliferating cells was recorded as the number of Ki-67-positive cells divided by the sam-
ple area (cm2). Percentages of Ki-67-stained myocytes in the lesion area, in the border area and 
in	the	remote	area	were	assessed.	The	total	proliferation	index	was	defined	as	the	proportional	
amount of Ki-67-positive cells in the lesion area, in the border area and in the remote area.
During the myoblast cultivation, the cell lineage was evaluated by the expression of desmin 
(study	 IV).	The	cells	were	fixed	 in	–20°C	methanol,	washed	with	PBS,	 and	 incubated	with	
monoclonal anti-desmin antibody for 1 hour. They were then washed with PBS and incubated 
with horseradish peroxidase-conjugated anti-mouse secondary antibody (Dako, Glostrup, Den-
mark). Immunoreactivity was visualized using the 3-amino-9-ethyl-carbazole (AEC) chro-
mogen. The cells stained 80-90% positive for desmin.
For	 localization	of	 skeletal	myoblasts	post	mortem,	skeletal	muscle	specific	anti-nebulin	
immunohistochemistry was used. Collagen was stained with Van Gieson’s stain. The sam-
ples were analyzed under a light microscope (Olympus Optical) by an experienced patholo-
gist blinded to randomization. Photographs of histologic sections were taken with an Olympus 
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AX70 microscope (Olympus Optical) and analySIS software (Soft Imaging System). The im-
munostained	sections	were	photographed	in	five	random	spots	and	the	pixel	intensity	values	
were limited to 8 bits per sampled pixel (range of values, 0-255). The cut off point for staining 
was set on a pixel value of 60/255 shades of gray, and the stained pixel fraction was counted 
using imageJ software (National Institutes of Health, USA).
Other examination methods
Imaging of retina
Adverse retinal neoangiogenesis was assessed (study I). Dilatation of the pupils was carried out 
with 0.5 % tropicamide, and 10% phenylephrine. Central retinal area around the papilla was 
photographed by a Genesis Hand-Held Fundus Camera Camera (Kowa Europe, GmbH, Dus-
seldorf,	Germany)	and	Kodakrome	Elite	100	ASA	film	(Eastman	Kodak	company,	Rochester,	
NY, USA). A total of six eyes of three animals in the adVEGF-C group, and four eyes of two 
animals in the adLacZ group were photographed. Interpretation of retinal neovascularization 
was executed by an experienced ophthalmologist blinded to treatment groups.
Statistical methods
Data	were	analyzed	in	a	blinded	fashion.	Paired	t-test		was	used	to	test	the	significance	of	dif-
ference between two time points in within one group, when Gaussian distribution was assumed 
(study I-III). When non-Gausssian distribution was assumed, Wilcoson test was used (study 
IV). Different groups were compared with two-tailed non-paired t-test in case of Gaussian dis-
tribution (study I-III) and with Mann-Whitney test in case of non-Gaussian distribution (study 
IV). Fisher’s exat test was used with contingency tables (study IV). Data was presented as mean 
± SEM (Study I) or as median and range (study II-IV). Differences between multiple factors 
were compared with Kruskall-Wallis test (study III). A p-value less than 0.05 was considered 
statistically	significant	
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Figure 1. Study protocols. Study protocols. Ameroid is a slowly swelling ring applied around coronary 
artery, causing gradually increasing stenosis of a coronary artery. Angiogenic gene therapy was car-
ried out with vascular endothelial growth factor-C (study I). Ligation of the narrowed coronary vessel 
was performed in a phase of nearly occluded artery, when already formed collateral vessels would 
protect the myocardium from excessive infarction (study II-IV). Autologous myoblasts were harvested 
from vastus muscle and after cultivation of 2 weeks the cells were injected directly to the myocardium 
(study IV). SPECT = single emission computed tomography, 18-FDG PET= 18-fluorodeoxyglucose 
positron emission tomography, MRI= magnetic resonance imaging.
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6. Results
Study I
Overall assessment
Survival of the animals was 12 out of 15, and mortality was 20%. Median weight of the animals 
was 34 (range 27 to 42kg) at three weeks and 61 kg (range 50 to 73kg) at 7 weeks. One animal 
developed an infarct at the lateral LV wall, which comprised 6% of the LV mass according to 
SPECT studies. Retinal photograph was unable to detect any neovascularization in the exam-
ined retinas. Adverse effects of adVEGF-C or adLacZ were not found in any of the animals.
Progression of the LCx stenosis durig the study
Pretreatment angiography at three weeks after the Ameroid placement showed a median 75% 
stenosis in LCx, range 75 to100% in the adVEGF-C group. The LCx stenosis at 7 weeks, had 
progressed	to	median100%,	range	90	to	100%	(p=0.041,	Wilcoxon	test).	In	the	adLacZ	group,	
the stenosis at three weeks’ was median 75%, range 60-75% and progressed to median100%, 
range	85-100%	at	seven	weeks’	(p=0.042,	Wilcoxon	test).	The	degree	of	LCx	stenosis	did	not	
differ	between	groups	at	3	weeks’	or	at	the	7	weeks’	angiography	(p=0.15	and	p=0.64,	respec-
tively, Mann-Whitney test).
Angiographic evidence of the collateral vessel formation
Significant	 collateral	 vessel	 formation	 was	 detected	 in	 both	 groups	 between	 3-weeks’	 and	
7-weeks’ angiographies. In the adVEGF-C group, the median Schwartz grade at 7-weeks’ an-
giography was median 2.75, range 2.0 to 3.0 and in the LacZ group, median 2.0, range 1.0 to 
2.5	(p=0.052,	Mann-Whitney	U-test).	The	treatment	area	index,	which	measures	the	relative	
amount	of	collateral	vessels	at	 the	injection	site,	demonstrated	a	significant	accumulation	of	
collaterals in the treatment area when the adVEGF-C group was compared to the LacZ group 
(p=0.004,	Mann-Whitney	U-test).
Evaluation of the 18-FGG PET
Change in myocardial metabolic substrate plays a key role, when ischaemic myocardium is 
judged by positron emission tomography. Ischemic myocardium favours the use of glucose over 
fatty acids, and 18F-FDG glucose analogue cellular uptake increases in a hypoperfused myo-
cardium. Semiquantitative assessment of 18F-FDG uptake suggested improvement in myocar-
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dial substrate change in the LCx region in the adVEGF-C group, when compared to the control 
group	(p=0.052,	Mann-Whitney	U-test).	
Measurement of myocardial perfusion by SPECT 
Myocardial perfusion judged by 99Tc sestamibi SPECT detected no difference between the 
adVEGF-C	and	adLacZ	groups	(p=0.34,	Mann-Whitney	U-test).	Global	and	local	systolic	wall	
thickening was measured by 99Tc sestamibi SPECT. Local systolic LV wall thickening in the 
LCx	area	decreased	during	the	study	period	in	the	LacZ	group	(p=0.042),	whereas	the	decrease	
at	the	same	area	in	the	VEGF-C	group	did	not	reach	statistical	difference	(p=0.10).	Similarly,	
global	LV	wall	thickening	in	the	LacZ	group	deteriorated	significantly	(p=0.043),	while	the	ad-
VEGF-C	group	preserved	the	pretreatment	status		(p=0.50)	despite	progressive	LCx	stenosis.	
Decrease in LVEF during dobutamine stress compared to rest imaging is highly indicative 
of myocardial ischaemia. Decrease in stress EF to the corresponding rest EF was a median 
9% (range –28-16%) in the adVEGF-C group, and 6% (range 4-17%) in the LacZ group. At the 
7-week study, decrease was a median 8% (range –8-23%) in the adVEGF-C group and a me-
dian 13% (range 11-38%) in the adLacZ group. Difference between the groups at 7-weeks was 
insignificant	(p=0.09).	Deterioration	in	LVEF	between	3	and	7	weeks	was	more	evident	in	the	
LacZ	group	(p=0.043,	Wilcoxon	test),	whereas	the	VEGF-C	group	suggests	a	similar	course	in	
LVEF	(p=0.091,	Wilcoxon	test).
Histological evaluation of the microvessel count
We were unable to discover any adverse effects in either group in the treatment area, or oth-
er	parts	of	the	myocardium.	Diffuse	fibrosis	and	lymphocytic	infiltration	were	found	in	both	
groups lateral wall at the area of ischaemia and injections. Myocardial samples at the treatment 
area in the adVEGF-C group showed more microvessels in the Von Willebrand factor stain-
ing	compared	 to	 the	adLacZ	group	 (p=0.03,	Mann-Whitney	U-test).	Apical	control	 samples	
remote	of	the	injections	showed	no	difference	in	microvessel	count	between	groups	(p=0.15,	
Mann-Whitney	U-test).	 Enlarged	microvessels	 in	αSMA	 immunostaining	was	 found	 in	 the	
adVEGF-C group at the site of injections at 6 days after gene transfer, but not in the adLacZ 
group.
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Study II-III
Overall assessment
Eight animals out of 11 survived the whole study period (mortality was 27%).  Median weight 
of the animals was 63kg (range 59 to 76). Two animals died due to banding, and one animal 
died because of displacement of intubation tube. 
LCx stenosis after the ligation procedure
Mortality in the ligation group was 3 animals out of 11 (27%). One week after banding of the 
Ameroid-stenosed LCx artery, angiography showed subtotally or completely occluded in all 
but one animal. In this animal the stenosis was estimated as 87% one week after the ligation, 
but second angiography revealed total occlusion four weeks later. Rentrop grade of the lateral 
wall	 collaterals	was	 2.7±0.4	 and	 2.5±0.5	 at	 one	 and	 five	weeks	 after	 banding,	 respectively	
(p=n.s.).	When	the	stenosis	after	the	ligation	was	compared	to	the	angiography	of	12	animals	of	
the	study	I	at	three	weeks,	significantly	more	constant	stenosis	was	shown	(p=0.0009).	
LV infarction measurement 
Stress SPECT compared to the respective rest SPECT showed stress-induced perfusion defect 
at	one	week	after	the	banding,	which	resolved	until	the	final	study.	The	perfusion	defects	were	
localized at the LCx area; other areas showed normal perfusion. Recovery of the perfusion 
at	five	weeks	after	banding	was	statistically	significant	comparing	to	the	one	week’s	studies	
(p=0.02,	paired	t-test).	
In	MRI,	Myocardial	scar	was	seen	in	five	animals	but	not	in	three	animals.	There	was	100%	
agreement in the detection of myocardial scar in individual animals between the PET, SPECT 
and	MRI	studies.	Scar	size	assessed	by	MRI	decreased	significantly	from	one	week	(10.5%	±	
7.9%)	to	five	weeks	(6.8%	±	5.3%,	p=0.03,	paired	t-test).
PET	images	showed	static	irreversible	perfusion	defects	in	five	animals.	SPECT,	MRI	and	
PET had 100% agreement in the detection of scar. There was a considerable amount of indi-
vidual variation in glucose uptake in the lesion area. The animals with a detectable scar on 
MRI had a decreased glucose uptake. Two of three animals, which had no detectable scars in 
MRI had an increase in the glucose uptake (as a sign of myocardial ischemia), and the third ani-
mal had near-normal glucose uptake in the LCx area at the one week study. The animals with 
abnormal glucose uptake at one week showed a shift towards a less deranged glucose uptake at 
five	weeks	and	energy	consumption	improved	significantly	over	time	(p=0.03,	paired	t-test).
In histology all but one animal showed myocardial infarction in HE-staining, including the 
prematurely died individuals. Most common myocardial lesion area was transmural myocar-
dial infarction at least 5 cm2 and other animals showed scattered subendocardial scar. Location 
was left ventricular lateral wall with some extension to the inferoposterior region. Interestingly, 
the two animals with largest transmural scars (up to 12 cm2) were those with biggest antegrade 
collaterals seen at the second angiography. In one animal with strongly right dominant coro-
nary anatomy, only a small subendocardial scar was detected at the lateral wall. The animal 
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with non-occluded LCx at one week after the ligation showed no macroscopic scar but diffuse 
fibrosis	in	histology,	indicating	ischemia	at	the	lateral	wall.	
Border area ischemia at the infarct penumbra   
 Stress SPECT studies compared to the corresponding rest SPECT studies showed that a per-
fusion defect was induced at one week after banding, but that the defect had resolved by 5 
weeks.	The	difference	between	 these	 two	 study	points	was	 statistically	 significant	 (p=0.02,	
paired t-test). On MRI, the difference between signal intensity change rate in the LCx area and 
the	control	area	was	a	median	of	34˚	(range	19˚-59˚)	at	one	week	and	15˚	(range	0˚-34˚)	at	five	
weeks	after	banding	(p=0.0065,	paired	t-test).		
Systolic function assessed by MRI 
At one week after banding, MRI showed a reduction in the systolic LV-wall thickening of the 
lateral wall compared to non-ischemic parts of the myocardium. The systolic LV wall thicken-
ing	at	the	lateral	wall	had	improved	significantly	at	five	weeks	(p=0.03,	paired	t-test).	A	sugges-
tive	increase	in	the	LVEF	was	measured	on	the	MRI	at	five	weeks’	study	compared	to	the	one	
week’s	study	(p=0.06,	paired	t-test)
Diastolic function assessed by MRI
The	early	filling	volume	of	the	LV	increased	significantly	in	five	weeks	compared	to	one	week	
(p=0.039,	paired	t-test).	There	was	also	a	significant	increase	in	the	PFR	(p=0.0078,	paired	t-
test),	but	no	change	in	the	time	to	peak	filling	rate.	
Histological evaluation of cardiomyocyte proliferation 
Immunohistological staining of the von Willebrant factor revealed clusters of neovasculari-
zation especially at the scar areas and areas close to the infarction. Myocardial muscle cells 
stained positive for desmin. Proliferation-associated nuclear antigen Ki-67 was located in the 
myocytes, lymphocyte-resembling cells and, occasionally, in endothelial cells. The median 
number of dividing myocytes was 4.8 cells (range 0-48)/ cm2. The number of dividing myo-
cytes	was	 higher	 in	 the	 distant,	 non-infarcted	 area	 of	 the	 lesion	 (p=0.037,	 paired	 t-test).	 In	
contrast, the total cell proliferation index was lower in the distant myocardium than at the le-
sion	area	where	clusters	of	non-myocyte	cell	proliferation	were	seen	in	the	scar	(p=0.02,	paired	
t-test). COX-2 and macrophage marker expression was unaffected.  
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Study IV
Overall assessment
Mortality of all animals was 66%, 15 survived out of 44. Four animals died at the time of 
Ameroid application, 15 died in the ligation procedure, 1 died in the transplantation, and 9 
died	 during	 the	 imaging	 procedures.	 Sustained	 ventricular	 fibrillation,	with	 no	 response	 to	
electrical or pharmacological cardioversion was present in almost all cases. Mortality after 
myoblast transplantation was 2 animals out of 11 (18%). In control group, all animals survived 
after injection of the control medium. Assessed from the time point of treatment injections, 
there	was	no	difference	in	mortality	(p=0.51,	Fisher’s	exact	test).	Median	weight	of	the	animals	
was 21 kg, range 18 to 26 kg, at the beginning of the study and median weight at the end of the 
study was 61 kg, range 50 to 73, with no differences between the groups. All animals showed 
ischemic	changes	in	histology.	There	was	increased	fibrosis	in	all	animals	with	no	differences	
between the groups. In the myoblast group, myoblasts coud be found at the site of injections 
aligning	the	fibrotic	area.	
In vivo and histlogical evaluation of neovascularization 
One week after the ligation, the pretreatment angiography in the myoblast transplantation group 
showed a median 100% stenosis in LCx, range 85 to 100%. At 5 weeks after the ligation, the 
LCx	stenosis	was	median	100%,	range	90	to	100%	(p=	n.s.,	Wilcoxon	test).	In	the	control	group,	
the stenosis at three weeks’ was median 100%, range 90% and 100%, range 90-100% at seven 
weeks’	(p=n.s.,	Wilcoxon	test).	The	degree	of	LCx	stenosis	or	the	size	of	the	LCx	vessels	did	
not differ between between the groups. Filling of the LCx via collaterals according to Schwartz 
grade did not differ between the groups.
MRI	perfusion	measurements	 showed	median	 slope	difference	22°(range	12-64°)	 in	 the	
myoblast	group	on	the	pretreatment	MRI	and	12°(range	5-28)	on	post-treatment	MRI	(p=0.09).	
The	median	slope	difference	in	the	control	group	on	pre-treatment	MRI	was	18°(range	0-42°)	
and	on	post-treatment	MRI	was	12°(range	0-22,	p=0.12).	The	change	in	slope	difference	did	not	
differ	between	the	groups	(p=0.56),	indicating	similar	amount	of	ischemia	between	the	groups	
in the pretreatment and post-treatment studies. 
Microvessels stained by anti-vWf were seen more frequently in the myoblast group at 
the cell transplantation area at the lateral left ventricular wall compared to the control group 
(p=0.045).		
Diastolic function after myoblast transplantation
MRI	indicated	improved	diastolic	filling	in	the	myoblast	group,	but	not	in	the	control	animals	
according to change in PFR between pre- and posttreatment studies. In the myoblast group, the 
median PFR was 279 ml/s, range 146 to 441 at one week after the ligation and median 479 ml/s, 
range	226	to	1012	at	five	weeks	after	the	ligation	(p=0.0048).	The	median	PFR	in	the	control	
animals at one week after the ligation was median 279 ml/s, range 221 to 511 and median 339 
ml/s,	range	267	to	606	at	five	weeks	(p=0.18).	In	the	myoblast	transplantation	group,	DD	in-
creased from the pretreatment median 324 ms, range 169 to 528 into posttreatment median 535 
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ms,	range	266	to	590	(p=0.0039).	In	the	control	group,	pretreatment	DD	was	median	322	ms,	
range	225	to	465	at	and	posttreatment	median	was	389	ms,	range	250	to	537	(p=	0.44).	There	
was no change in the TPR in the myoblast group, nor in the control group between the pretreat-
ment and posttreatment studies. Heart rates were equal between the groups at pretreatment and 
posttreatment studies. 
Systolic function after myoblast transplantation 
In the myoblast group, LVEF was median 51%, range 29% to 69% at the pretreatment MRI and 
median	50%,	range	44%	to	65%	in	the	posttreatment	MRI	(p=0.18).	In	the	control	group	LVEF	
was 57%, range 42% to 62% in the pretreatment MRI and median 49%, range 41% to 65% at 
the	postttreatment	MRI	(p=0.56).	There	was	no	difference	between	the	groups.	Local	systolic	
thickening at the lateral LV wall at the LCx area, showed no improvement in either groups. In 
the myoblast transplanted animals, PER was 277 ml/s, range 155 to 604 in MRI at one week af-
ter	the	ligation	and	median	389	ml/s,	range	211	to	655	at	five	weeks	after	the	ligation	(p=0.049).	
In the control animals PER was median 266 ml/s, range 205 to 439 at one week and median 389 
ml/s,	range	211-655	at	five	weeks	after	the	ligation	(p=0.84).
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7. Discussion
Porcine Ameroid model 
Porcine has many advantages in modelling acquired human heart disease. First, macroscopic 
anatomy of porcine heart structure resembles closely human (Crick and others 1998b). Second, 
coronary	anatomy	and	individual	variation	in	the	blood	supply	of	the	LV	fluctuates	similarly	
to man (Weaver and others 1986).   Third, pre-existing collateral vessels are similarly sparse 
in both species (Maxwell, Hearse, Yellon 1987). Fourth, the size of porcine makes possible to 
utilize examination methods developed for humans (Hughes 1986). Fifth, similarly in both spe-
cies	myocardium	primarily	uses	nonesterified	fatty	acids	as	the	preferred	substrate	under	nor-
mal conditions, whereas during myocardial ischemia, the oxidation of fatty acids diminishes 
concomitant with increased glucose metabolism (Abdel-Aleem and others 1999). 
Ameroid constrictors have been widely used to produce slowly progressing coronary artery 
stenosis in animal models of myocardial ischemia (Hughes and others 2003). When Ameroid 
constrictors	were	immersed	in	physiologic	saline,	rapid	expansion	during	the	first	two	weeks	
was followed by a slow progress (Berman and others 1956). Anyhow, in vivo changes in the 
physiological environment and material might affect the ability of the constrictor to absorb 
water (Adin and others 2004), which is the prerequisite for the expansion. Also, variations of 
coronary vessel distribution and size might lead to inadequate and inaccurate vessel occlusion 
or unpredictable myocardial lesion. Large myocardial infarction after fast occlusion of the Am-
eroid should be avoided in the experimental setting for myocardial ischemia and angiogenesis 
(Unger 2001). However, in studies of heart failure, myocardial loss and scarring is required for 
sufficient	LV	dysfunction,	to	show	the	hypothetical	treatment	efficacy	
In	our	first	series	(study	I)	we	showed	variability	in	the	Ameroid	occlusion	rate	similar	to	
previous reports (Litvak, Siderides, Vineberg 1957; Nakai and others 2005; Sereda and Adin 
2005). At three weeks after the Ameroid application the mean stenosis was only 78%. Although 
severely stenosed at seven weeks after the Ameroid application (mean 95%), every fourth of 
coronaries were still patent. The unevenness of the occlusion rate can cause a requirement for 
larger animal cohorts. However, in our study of intramyocardial anngiogenic gene therapy, we 
could	show	a	significant	increase	in	Ameroid-induced	stenosis,	and	progressive	stenosis	provid-
ed a model similar in comparison with exertion ischemia. Control group showed also spontane-
ous	development	of	significant	collateral	circulation.	This	must	be	kept	in	mind,	when	assessing	
effects	of	collateral	formation	of	certain	treatment.	Proper	control	group	and	sufficient	amount	
of animals is a perquisite for a well-conducted study.  Difference between juvenile and adult, or 
healthy and diseased myocardium to produce collateral vessels might also elucidate part of the 
spontaneous growth of the collateral vessels in animal studies, when compared to the human 
studies (Gaffney and others 2007). 
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Modification of the Ameroid model
We chose to generate more consistent coronary artery occlusion than the standard Ameroid 
model. For simplicity, non-absorbable suture applied during the primary surgery was used 
to occlude the Ameroid-narrowed coronary artery. Time point of ligation was chosen by the 
knowledge of already formed collaterals at three weeks, which would protect the affected area 
from	a	massive	infarct.	A	rather	uniform	occlusion	was	produced,	with	significant	improve-
ment of the occlusion rate compared to our previous series of Ameroid occlusion without the 
ligation. The ligation process caused an infarct at the LCx perfusion area with relatively con-
sistent lesions. 
We	studied	the	natural	healing	of	the	new	model.	Our	main	findings	were,	that	perfusion	
at the border area improved, scar size diminished and local and global function of the LV im-
proved	in	both	systolic	and	diastolic	measures.	The	findings	we	were	able	to	show	in	a	large	
scale of examination methods. We used cardiac MRI, SPECT, PET and angiography. All the 
modalities showed congruent results. 
The	most	salient	findings	include	scar	diminishment,	which	is	of	significant	importance	if	
this model is to be used in a model of cellular transplantation after myocardial infarct. How-
ever, similar results have previously been introduced in both animal models as well as in hu-
mans (Holmes and others 1994; Holmes, Nunez, Covell 1997; Hombach and others 2005). The 
amount of the scar was measured by late enhancement images of MRI. Scar shrinkage is prob-
ably part of the healing process as seen in clinical cases. There is also possibility of inaccurate 
delineation of the scar due to odema at the early stages of infarcted myocardium. 
The functional improvement of the LV is most evidently explained by improved perfusion 
and reversal of hibernation and stunning (Fallavollita and Canty 1999; Fallavollita, Logue, 
Canty 2001) Hibernating myocardium and stunning to co-exist (Hughes and others 2001b) in 
the Ameroid swine model. In our study, there was no mean rest ischemia according to SPECT, 
which suggests that the myocardium is globally stunned, although viable myocardial regions 
with	chronically	impaired	resting	function	may	have	normal	or	reduced	myocardial	blood	flow	
at rest. There was variation in the FDG uptake between individual animals. Because the ani-
mals developed variably both ischemia and infarction in the region of interest, the 18-FDG-
PET deposition varied.  The imaging method allowed acquisition of only one image of full 
thickness LV wall, and the transmural variations of 18-FDG uptake could not be spatially 
separated. Thus, the image is the sum of subendocardial, midmyocardial and subepicardial glu-
cose metabolism. There are known differences in the 18-FDG uptake between these regions. 
While 18-FDG uptake is reduced in the infarcted myocardium and increased in the ischemic 
myocardium, the summation effect on the 18-FDG uptake might be neutral.  Nevertheless, all 
animals	had	less	deranged	18-FDG-uptake	five	weeks	versus	one	week	after	ligation,	a	finding	
that is consistent with improved perfusion and a reduction in the amount of nonviable myocar-
dium.	Although	both	scar	and	ischemic	myocardium	were	present,	the	finding	of	myocardial	
functional improvement showed clearly that ischemia was reversible. 
We measured the amount of the myocyte nuclei in mitosis at the time of eutanasia. The 
mitotic myocyte nuclei were located at the remote part of the LV to the area of the ischemic 
myocardium. This could indicate compensatory activation of remote parts of the myocardium. 
So far, evidence of distant myocyte proliferation in the presence of stunning or hibernating 
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heart is sparse (Lim and others 1999). Compensatory activation of myocytes distal to the lesion 
area	warrants	further	studies	to	demonstrate	the	functional	benefit.	The	value	of	this	kind	result	
from an experimental model is strengthened by the similarity between human and porcine car-
diac anatomy and CV disease progression. The number of proliferating myocyte nuclei at the 
time of eutanasia was rather low, which does not support a suggestion that myocyte prolifera-
tion might substantially affect LV function. Furthermore, the proliferation of the myocytes was 
only measured at one time point.
 Our aim was to create a simple and easily reproducible myocardial model to regulate and 
to	standardize	the	myocardial	lesion	as	a	modification	of	the	Ameroid	constrictor	model	and	to	
assess the consequent spontaneous response of myocardial perfusion and collateral formation. 
Our hypothesis was that adaptation to ischemia before banding would reduce arrhythmia in-
duced sudden death after coronary occlusion, and that timing of the coronary occlusion would 
result in a uniform infarction and thus, improve the usefulness of Ameroid constrictor model 
for preclinical studies of gene and/or cellular therapy. Staged banding of the Ameroid-stenosed 
vessel after initial ischemic adaptation of the myocardium seems a substantial improvement 
The spontaneous improvement of left ventricular ischemic lesion must be taken into considera-
tion in this model. 
Angiogenic potency of VEGF-C 
This	is	the	first	large-animal	angiogenic	study	demonstrating	adenovirus-mediated	VEGF-C	
gene transfer-induced collateral formation and the maintenance of myocardial function in pro-
gressive myocardial ischaemia. Our model of progressive stenosis provides a state, where natu-
ral healing process during increasing ischemia acts in concert with the therapeutic agent. In 
this setting, the inherent ability of myocardium to recuperate ischemia seems to be positively 
influenced	by	adVEGDF-C	transfer.	We	are	unable	to	show	the	mechanism	of	therapeutic	ac-
tion of the adVEGF-C, but the difference in perfusion with the control group suggests action 
via VEGF-C overexpression, rather than the adenoviral effect. Coronary artery disease patient 
have ischemic myocardium only during exercise, when patients with unstable angina are ex-
cluded. Thus similar condition to our model can be achieved clinically with exercise-induced 
angina.
In our study, we used SPECT data in the analysis of LV wall thickening and movement. In 
our SPECT, 24 images were obtained by ECG gating between one R-R-interval. Thus, a reliable 
functional status can be obtained, even when compared to MRI (Bax and others 2000). The 
increasing stenosis of the LCx caused deterioration of systolic thickening in the LacZ control 
group, but the VEGF-C treatment was able to reverse this deterioration. Anyhow, perfusion 
maps were unable to show difference between the groups. This might be due to the overall 
insensitivity of SPECT to detect minor differences in myocardial ischemia. 
Development	of	collateral	vessels	was	significant	in	both	groups.	Anyhow,	in	the	VEGF-C	
group, the collateral vessels were more clustered at the area of injections, when compared to 
the control group. This focal effect of VEGF-C overexpression was further evidenced by histo-
logical samples, in which more microvessels were seen at the area of injections. We measured 
the microvessels with anti-von Willebrand factor immunostaining, which does not differentiate 
blood vessel endothelium from lymph vessel endothelium. 
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Metabolic assessment by 18-FDG-PET showed deterioration in the control group, when the 
treatment group improved or remained the same. Similarly to the LV wall thickening, this sug-
gests	beneficial	effect	of	the	VEGF-C	gene	transfer.	Interestingly,	when	PET	studies	were	per-
formed	three	times	during	the	study	period,	the	highest	glucose	uptake	was	at	five	weeks	after	
the Ameroid placement, thus indicating the probable time scale of the Ameroid occlusion. 
Individual variation of the size of the LCx and right coronary artery is similar to man in 
porcine. This variation must be considered, when porcine is used as a model of collateral de-
velopment. We used two independent interpreters blinded to the randomization to estimate the 
LCx size. In a semiquantitative analysis no differences between the groups could be found. 
In a model of ischemic rabbit hidlimb, VEGF-C induced collateral formation, when admin-
istered both as recombinat protein or plasmid gene transfer (Witzenbichler and others 1998). 
Increased endothelial mitogenesis and migration as well as increased nitric oxide release after 
VEGF-C administration was shown in vitro. In the in vivo setting, angiogenesis and collateral 
formation was shown in the VEGF-C treated animals anatomically by angiography, physiologi-
cally by calf pressure measurement and also histologically.  
In a clinical study of plasmid VEGF-C gene transplantation by intramyocardial injections 
for myocardial ischemia by Losordo et al. (Losordo and others 2002), similar results were 
observed. In this dose escalating study, 18 patients received plasmid VEGF-C by intramyocar-
dial injections and were compared to 9 patients receiving saline. Double blind analysis of the 
material	showed	statistically	significant	reduction	in	anginal	class	and	analysis	of	the	SPECT	
and electromechanical mapping showed suggestive improvement in the VEGF-C gene transfer 
group. VEGF-C has been lately shown to primarily act on lymphatic tissue development and 
regeneration (Saaristo and others 2002), but overlapping in receptor binding with other VEGFs 
suggests that VEGF-C might have potency in the treatment of ischemic disorders. VEGF-C 
has also shown to act in a therapeutic manner in neointimal hyperplasia (Hiltunen and others 
2000). 
We showed collateral vessels clustering at the site of adVEGF-C therapy at 4 weeks after 
the injection. According to previous reports, at that time the adenoviral expression should al-
ready ceased off (Rutanen and others 2004c). Other VEGFs, such as VEGF-A and VEGF-D 
transfected with adenovirus has shown results similar to ours (Lee and others 2000a; Rutanen 
and others 2004b). This large animal study suggests the potential of VEFG-C gene transfer in 
the treatment of myocardial ischemia. 
Myoblast transplantation in a porcine model
In our study, cardiac diastolic function improved in the animals receiving autologous myob-
lasts. The cells were transplanted at the area of ischemia and infarction. The improvement was 
shown in cardiac MRI. Our model closely mimicks the course of human coronary disease on 
a large experimental animal setting. Our data demonstrate that transplantation of autologous 
myoblasts after brief expansion, effects comparable to extensive cultivation as reported for 
example in the Magic-trial, which showed improvement in myocardial remodelling (Menasche 
and others 2008b). 
The basis of the improvement in diastolic properties of the myoblast-transplanted hearts 
remains	obscure.	We	could	find	more	microvessels	at	the	myoblast	injection	area,	which	indi-
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cates improved local perfusion and oxygen supply. Anyhow, macroscopic perfusion studies in 
cardiac MRI did not show difference compared to the control animals, nor did angiography 
show	difference	in	collateral	assessment.	Thus	the	improved	perfusion	remains	unconfirmed.	
In an animal study of myoblast transplantation enhancement of myocardial oxygenation was 
shown at the site of cell transplant compared with untreated control hearts. Skeletal myoblasts 
were labeled with oxygen sensing probes before further transplantation to heart (Wisel and 
others 2007). According to this, our methods of perfusion assessment might be insensitive 
to reach minor differences. Nevertheless, our methods are widely clinically used and reliably 
show	clinically	significant	changes	(Lauerma	and	others	1997).
We	used	modified	Ameroid	model	to	mimic	diastolic	dysfunction	caused	by	coronary	artery	
disease. The progressively stenosing coronary artery generates collateral dependent ischemic 
myocardium and the further ligation of the stenosed vessel results in infarction with border 
ischemia. The anatomical and physiological similarity of porcine and human heart enables 
to study the most common type of diastolic dysfunction, caused by myocardial ischemia. In 
our	model,	both	the	reduced	myocardial	blood	flow,	as	well	as	the	increased	fibrosis	leads	to	
reduced	and	delayed	LV	filling.	Other	causes	 for	 relaxation	disturbancy	 include	myocardial	
hibernation, stunning and possible odema due to myocardial infarction. 
According	 to	Frank-Starling	 law,	diastolic	filling	 is	 a	 significant	determinant	of	 systolic	
contractility. Thus in oours study, the increase in peak ejection rate was expected as diastolic 
preload was increased. Based on our observations, the myoblast-transplanted hearts seemed 
to	function	more	efficiently	performing	systolic	work	in	a	reduced	time.	However,	it	should	be	
emphasized, that the duration of diastole, duration of systole and LV ejection rate are all deter-
minants of the same cardiac cycle and are correlated to each other. When both the length and 
duration	of	the	LV	filling	slope	are	increased,	obviously	the	slope	of	the	LV	emptying	is	also	
increased.	In	contrast	to	the	beneficial	effects	observed	in	diastolic	functional	parameters,	no	
effect was evident in systolic parameters such as LV thickening at the site of myoblast trans-
plantation or LVEF. 
Myoblast transplantation in a cryoinjury model preserved static stiffness of the LV wall 
and increased strain as well as resting myocardial segment length was shown. These changes 
suggested improved compliance of the LV wall, implying that myoblasts make the myocardium 
more responsive in stretch than plain scar (Atkins and others 1999). In another study, bone mar-
row cell transplanted hearts were related with reduced collagen density and improvement of 
diastolic function was seen (Nagaya and others 2004). Angioblasts and mesenchymal stem cells 
has also been shown to reduce collagen in the LV wall after AMI (Kocher and others 2001b). 
We assessed the amount of collagen histologically in both groups to measure the effect of my-
oblast	transplantation	to	fibrosis,	but	we	were	unable	to	show	difference	between	the	groups.	To	
demonstrate the detailed mechanisms behind the improving diastolic properties, further stud-
ies are warranted.  The main limitations of the study include the small number of the animals. 
Also, parallel use of echocardiography might have been advantageous, since echo is the clincal 
standard of diastolic mesurement. Longer surveillance might have provided information of the 
long-term effects of the myoblast transplantation. 
Our study suggests, that systolic function is not the sole determinant of the advantage of my-
oblast transplantation. Despite the evident disappointment in the negative results in the primary 
endpoints	of	MAGIC	trial,	there	was	evidence	of	beneficial	effects	in	remodelation	(Menasche	
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and others 2008a). Similar results have been shown in nonrandomized studies with myoblast 
sheet technology (Sawa 2007). Myoblasts possess several advantages. The cell can be easily 
harvested	and	proliferated	and	thus	there	is	no	need	for	immunosuppression	and	a	significant	
amount of cells can be generated in a relatively short time. Myoblasts keep the ability to con-
tract	by	differentiating	into	myotubes	and	myofibrils.	Although	the	lack	of	electric	coupling	is	
acknowledged, the cells are able to contract upon mechanical signalling.   Myoblasts are resist-
ant to ischaemia compared to the progenitor cells and despite the high cellular death reported 
after transplantation, methods to improve cell survival are under development. The main effect 
of the myoblast transplantation has been recently proposed to be explained by paracrine effects 
(Formigli and others 2007; Menasche 2007; Menasche 2008; Perez-Ilzarbe and others 2008). 
Our study shows the importance of large animal studies, in which clinically relevant data 
can de gathered. We also stress out the superiority of cardiac MRI in the large-scale assessment 
of cardiac function. Improved spatial resolution and faster imaging techniques in cardiac MRI 
show a new standard in examing heart volume and function.
Clinical relevance of recent studies
These studies show promising novel methods in the treatment of hypoperfused mammalian 
heart. The use of biological methods to improve perfusion and function of heart would be espe-
cially interesting in patients, who are amenable to recent treatment practise. Thus, patients with 
end-stage coronary disease or end-stage heart failure would present the frontline of the new 
therapy. However, the therapeutic effect of adVEGF-C warrants further studies to evaluate the 
true effect in human coronary disease. The results in a healthy young animal cannot be directly 
transferred in human cases, which have been selected by being not amenable to the ongoing 
treatment methods. The use of myoblast transplantation has been tested in humans in a rather 
large series (Menasche 2008), where the primary end point of systolic improvement did not 
show any affect. Anyhow, there were other effects, which might warrant new consideration of 
the treatment outcome. While these new treatment modalities are under development, testing 
of the therapeutic efect should be done in appropriate biological models. 
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8. SUMMARY AND 
 CONCLUSIONS
The present study evaluated VEGF-C over-expression angiogenic gene therapy and myoblast 
cell therapy in the treatment of coronary disease and heart failure. We used porcine coronary 
gradual stenosis and occlusion to model human coronary artery disease and its consequences. 
We made improvements in the standard Ameroid model and described the natural course of the 
new model. Intramyocardial autologous myoblasts were tested in this newly developed model.
I    Intramyocardial adenoviral VEGF-C gene transfer was carried out during progressive 
 occlusion of LCx coronary artery. In the VEGF-C treated animals heart function remained, 
 whereas in the adLacZ control animals the heart function deteriorated by increasing coro- 
 nary stenosis. More microvessels was clustered at the injection area. 
II	 Due	 to	 inconsistent	stenosis	produced	by	Ameroid,	a	new	modification	of	 the	Ameroid	 
 model was developed. With this new stenosis-ligation-model, more reliable stenosis could 
 be achieved with rather constant lateral LV wall infarction.
III  The spontaneous response of the heart to the new stenosis-ligation-model was shown by 
 MRI, SPECT, PET and angiography. A wide range of natural improvement was measured, 
 including systolic and diastolic LV improvement, reduced infarct size according to MRI 
	 and	improved	perfusion	confirming	recuperation	of	hibernation	and	stunning	at	the	border	 
 zone at the infarct penumbra area. Histological double-stainings were employed to meas- 
 ure the amount of cardiac regeneration by dividing cardiomyocytes, which indicated more 
 cardiomyocyte mitosis at the romote area of the infarct. 
IV Low dose myoblast transplantation at the area at risk of the newly developed model sug- 
 gested improvement of diastolic function of LV. We were able to locate the transplanted 
 cells 4 weeks after the transplantation. EF or local systolic thickening showed no improve- 
 ment, when compared to the control group
Our study suggests potential of VEGF-C treatment in the use of progressive myocardial 
ischemia. VEGF-C deserves further studies as a therapeutic option in cardiovascular disease, 
to become a viable option as a viable angiogenic treatment in coronary disease.
Inconsistent coronary occlusion in Ameroid constrictor model might disturb the experi-
mental setting in animal models of ischemia. By ligation of the Ameroid-stenosed proximal 
LCx coronary artery at three weeks after the Ameroid application, leads to consistent stenosis 
of the vessel as to reproducible infarction of the vessel. The natural healing process in this 
model must be taken into consideration when experimentally used.
Myoblast transplantation might have effect on cardiac function even when used in low dose 
setting. Suggestion of diastolic improvement was shown, whereas no improvement in systolic 
parameters was shown. 
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